Compensatory Relationship Between Exonic Splicing Enhancer, Splice Site and Protein Function by Falanga, Alessia
Open Research Online
The Open University’s repository of research publications
and other research outputs
Compensatory Relationship Between Exonic Splicing
Enhancer, Splice Site and Protein Function
Thesis
How to cite:
Falanga, Alessia (2012). Compensatory Relationship Between Exonic Splicing Enhancer, Splice Site and Protein
Function. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2012 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
u i^ R 6 S T f^ C T 6 P
Compensatory Relationship Between Exonic Splicing Enhancer, 
Splice Site and Protein Function 
Alessia Falanga
A Thesis Submitted in Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy in Life Sciences
International Centre for Genetic Engineering and Biotechnology,
ICGEB Trieste, Italy 
The Open University, UK
Director of Studies: Prof. Francisco E. Baralle, M.D. Ph.D. 
External Supervisor: Dr Colin Sharpe, MA DPhil.
October 2MN2
D(XtC SiAJbrm56ix)i^: 22 /W just 2011-
Code ol- f tw a rd :  25 October 201 z
ProQuest Number: 13835939
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 13835939
Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
Table of Contents
LIST OF FIGURES AND TABLES____________________________________________ 5
ABBREVIATIONS___________________________________________________________9
ABSTRACT________________________________________________________________11
L INTRODUCTION________________________________________________________ 12
N.N Overview of splicing__________________________________________________________ N2
N.2 Spliceosome complex formation_______________________________________________ N5
N.3 Alternative splicing: where a common precursor pre- mRNA______________________ N9
molecule can generate multiple mRNAs____________________________________________ N9
N.4 Donor and Acceptor splice site sequence________________________________________ 2N
N.4.N Relative strength and cooperation between signals_________________________________________ 25
N.5 Exon/Intron Architecture______________________________________________________25
N.6 Auxiliary splicing regulatory element___________________________________________ 28
N.6.N Enhancer Elements____________________________________________________________________29
N.6.2 Silencer Elements_____________________________________________________________________32
N.6.3 Bioinformatic analysis o f S R E __________________________________________________________33
N.7 Combinatorial Mechanism_____________________________________________________34
N.8 Protein evolution: An Overview_______________________________________________ 35
N.8.N Codon based model of protein evolution__________________________________________________ 37
N.8.2 Splicing and the evolution o f proteins in mammalian proteins_______________________________ 38
N.8.3 Alternative splicing and evolution_______________________________________________________ 4M
N.9 Impact of gene duplication on rates of molecular evolution  _______________________ 42
N.9.N Different mechanisms for paralogous genes preservation___________________________________ 42
N.NM Alkaline phosphatase gene family_____________________________________________ 45
2. AIM OF THE THESIS____________________________________________________50
5. RESULTS______________________________________________________________ 52
3.N ESE Analyzer Web Server (EAWS) computational analysis_______________________ 52
3.N.N Candidate protein families selected via EAWS____________________________________________ 58
3.2 Analysis of ESE bioinformatics predictions______________________________________ 64
3.2.N Analysis o f ALPP exon 4 processing after mutations in two regions where the presence o f ESE is 
predicted and associated with weak 3’ splice sites_______________________________________________68
3.2.2 Experimental validation o f ESE present in both ALPP and ALPL exon 4 and 5 respectively  73
3.2.3 Fine mapping o f the ESE _________________________________________________________ 77
3.2.4 The ESEs in ALPP are necessary due to a non consensus 3 ’ s s _____________________________  83
/
3.3 Testing the biochemical effect of the amino acid differences within the enhancer 
elements of PLAP and corresponding region of TNAP________________________________ 89
3.4 Setup of methodology for recombinant Human Alkaline Phosphatase protein expression 
_______________________________________________________________________________ 9N
3.4.N Purification and quantification o f wt FLAG secreted protein________________________________ 93
3.4.2 Evaluating purification yield____________________________________________________________ 95
3.5 Construction of protein expression vectors by site-directed mutagenesis of PLAP cDNA 
 NMN
3.6 Kinetic studies of A L Ps__________________________________ NM4
3.6.N Effect of Gly93>Ala and Ala94>Gly amino acid substitutions on the kinetic activity o f PLAP. NM9
3.6.2 Effect o f Argl25>Gln amino acid substitution on the kinetic activity o f PLAP______________  NN2
3.6.3 Effect o f Gly93>Ala, Ala94>Gly and Argl25>Gln amino acid substitutions on the kinetic activity 
of PLAP NN4
2
4. DISCUSSION____________________________________  118
4.N ESE Analyzer Web Server (EAWS) computational analysis. Identifying a candidate 
paralogous protein fam ily_______________________________________________________N2M
4.2 Validation of bioinformatics ESE predictions___________________________________ N22
4.3 Testing the biochemical effect of the amino acid differences within the enhancer 
elements of PLAP and corresponding region of TNAP, the protein products of ALPP and 
ALPL respectively _____________________________________________________________ N23
4.4 Alkaline phosphatase and evolution___________________________________________ N24
5. CONCLUSIONS_________________________________________________________130
6. MATERIALS AND METHODS___________________________________________ 131
6.N Chemical reagents___________________________________________________________ N3N
6.N.N Standard solutions___________________________________________________________________ N3N
6.2 Enzymes___________________________________________________________________ N3N
6.3 Synthetic oligonucleotides____________________________________________________N32
6.4 Bacterial culture____________________________________________________________ N32
6.5 Cell culture________________________________________________________________ N32
6.6 DNA preparation___________________________________________________________ N33
6.6.N Small scale preparation o f plasmid DNA from bacterial cultures___________________________ N33
6.6.2 Large scale preparations o f plasmid DNA from bacterial cultures_________________________  N33
6.7 RNA preparation from cultured cells______________________________________   N34
6.8 Estimation of nucleic acid concentration_______________________________________ N34
6.9 Enzymatic modification of DNA______________________________________________ N35
6.9.N Restriction enzymes__________________________________________________________________ N35
6.9.2 Large fragment o f E. coli Polymerase I and T4 Polynucleotide K inase_____________________  N35
6.9.3 T4 DNA ligase______________________________________________________________________  N36
6.NM Agarose gel electrophoresis of D NA__________________________________________ N36
6.NN Elution and purification of DNA fragments from agarose ge ls___________________ N37
6.N2 Preparation of bacterial competent c e lls______  N37
6.N3 Transformation of bacteria__________________________________________________N38
6.N4 Amplification of selected DNA fragments_____________________________________ N38
6.N6 Generation of minigenes_____________________________________________________ N39
6.N6.N PCR-directed mutagenesis___________________________________________________________  N39
6.N6.2 Quick Change Mutagenesis PCR method______________________________________________ N4N
6.N6.3 A complete list o f the primers used in the section 3 in this thesis__________________________ N42
6.N7 Maintenance and analysis of cells in culture___________________________________ N47
6.N8 Transfection of minigene plasmids___________________________________________ N48
6.N9 mRNA analysis by Polymerase Chain Reaction ________________________________ N48
6.N9.N cDNA synthesis____________________________________________________________________  N48
6.2M Construction of the expression plasmids.______________________________________ N49
6.2M.N Transfection o f expression plasmids__________________________________________________  N5M
6.2N Purification of FLAG-tagged enzymes________________________________________ N5N
6.22 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)____________________ N5N
6.23 Western blots and antibodies_________________________________________________N52
6.24 Micro Bicinchoninic Acid (BCA) Protein A ssay________________________________ N52
3
6.25 Immune Enzymatic Assay PLAP/TNAP______________________________________ N53
6.26 Slot blot protein determination______________________________________________ N53
6.27 ALP assay and Kinetic measurements________________________________________ N54
6.28 Statistical analysis__________________________________________________________ N55
7. REFERENCES________________________________________________________ 156
ACKNOWLEDGEMENT 165
4
LIST OF FIGURES AND TABLES
Figure 1.1 Schematic representation of the complex network during mRNA
processing....................................................................................................................14
Figure 1.2. Spliceosome assembly..................................  16
Figure 1.3. Schematic representation of sequential transesterification during splicing.... 18
Figure 1.4. Modes of alternative splicing..............................................................................20
Figure 1.5. Schematic representation of mammalian exon-intron boundaries and
consensus sequences for 5’ and 3’ splice sites and branch point..................... 23
Figure 1.6. Exon and Intron definition models..................................................................... 27
Figure 1.7. Models of SR protein action in exonic-splicing-enhancer-dependent
splicing...................................................................................................................31
Figure 1.8. Diagram showing the genomic organization of ALPL and ALPP genes.........49
Figure 2.1. The primary selective pressure on exons is for their inclusion in mRNA........51
Figure 3.1. Start page of ESE Analyzer Web Server (EAWS)........................................... 54
Figure 3.2. Page for selecting options in EAWS..................................................................56
Figure 3.3. A typical output page of EAWS for Ribonuclease A domain..........................57
Figure 3.4. Partial alignment of candidate gene families..................................................... 60
Figure 3.5. Output of EAWS showing the comparative analysis of the exon encoding
for the active site of human Alkaline Phosphatase (ALP) family.................... 63
Figure 3.6. Wild type splicing patterns of ALPP and ALPL minigenes............................65
Figure 3.7. Wild type splicing patterns of endogenous ALPP exon 4 processing............67
Figure 3.8. Analysis of ALPP exon 4 splicing after swapping the regions 1st and 2nd
ESE with that of ALPL........................................................................................70
5
Figure 3.9. Analysis of ALPL exon 5 splicing after swapping the regions 1st and 2nd
seq with that of ALPP.......................................................................................... 72
Figure 3.10. Putative ESE present in both ALPP and ALPL exon 4 and 5 respectively...74 
Figure 3.11. Analysis of ALPP exon 4 splicing after AG mutation in the 3rd putative
ESE......................................................................................................................76
Figure 3.12. Analysis of ALPP exon 4 splicing after mutations in the 1st ESE codons that
lead to amino acid difference in ALPL............................................................ 78
Figure 3.13. Analysis of ALPP exon 4 splicing after mutations in the 2nd ESE codons that
lead to amino acid difference in ALPL............................................................ 80
Figure 3.14. Analysis of ALPP exon 4 splicing after swapping of redefined regions 1st
and 2nd ESE with that of ALPL associated to amino acidic differences..........82
Figure 3.15. Analysis of ALPP exon 4 splicing after swapping of weak 3’ss with that
strong of ALPL exon 5 in minigenes that lack of ESE motifs.........................85
Figure 3.16. Analysis of ALPP exon 4 splicing after swapping of weak 3’ss with the 
stronger one of ALPL exon 5 in minigenes that lack of refined ESE
motifs....................................................................................................................86
Figure 3.17. Analysis of ALPL exon 5 splicing after swapping of strong 3’ss with the
weaker one of ALPP exon 4 ................................................................................ 88
Figure 3.18. Active site region of human PLAP....................................................................90
Figure 3.19. Recombinant Human Alkaline Phosphatase protein expression.................... 92
Figure 3.20. Purification of the FLAG secreted enzymes.................................................... 94
Figure 3.21. BSA concentration scale for the approximate estimation of
PLAP-FLAG yield.............................................................................................96
Figure 3.22. ALPs Immunoenzymatic assay (IEA).............................................................. 98
Figure 3.23 Slot blot detection of ALPs using anti-FLAG antibody................................. 100
6
Figure 3.24. Comparison between PLAP and TNAP amino acid sequence in a region that
includes the ESE sequences............................................................................. 102
Figure 3.25. An example of SDS PAGE gel at 10% stained with Coomassie Blue.........103
Figure 3.26. An example of/>nitrophenol formation measured as an increase in
absorbance at 405 nm (Abs 405) during the time AWmin (15 min).............. 106
Figure 3.27. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis
of p-NPP by wt PLAP-FLAG (A ) and wt TNAP-FLAG ( • ) ......................108
Figure 3.28. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis 
of p-NPP by wt PLAP-FLAG (A ) and PLAP-FLAG 1st ESE mut
[G93A;A93G] (* ) ............................................................................................I l l
Figure 3.29. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis 
of p-NPP by wt PLAP-FLAG (A ) and PLAP-FLAG 2nd ESE mut
[R125Q] ( ♦ ) .................................................................................................... 113
Figure 3.30. Box-plot showing the Michaelis-Menten constant (Km) in wt PLAP-FLAG, 
PLAP-FLAG 1st ESE mut [A93G; G94A] and
PLAP-FLAG 2nd ESE mut [R125Q]................................................................115
Figure 3.31. Box-plot showing the maximal rate of reaction (Vmax) in wt PLAP-FLAG, 
PLAP-FLAG 1st ESE mut [A93G; G94A] and
PLAP-FLAG 2nd ESE mut [R125Q]................................................................116
Figure 4.1. Possible evolutionary path of the ALP isoenzymes..........................................125
Figure 4.2. Two possible hypotheses to explain the temporal succession of changes
in splicing motifs in the ALP tissue-specific exon 4 ........................................128
Figure 6.1. Schematic representation ofpcDNA 3.1 minigene..........................................140
Table 1.1. Programs used to analyze splice sites...................................................................24
Table 1.2 Summary of gene nomenclature, protein names, chromosomal location and
function.....................................................................................................................47
7
Table 3.1. Kinetic parameters of ALP and mutants............................................................117
Table 6.1 Oligonucleotides List........................................................................................... 142
Table 6.2. Primers and templates used for the creation of each mutated minigene......... 145
8
ABBREVIATIONS
The standard abbreviations used in this dissertation follow IUPAC rules. All the 
abbreviations are defined also in the text when they are introduced for the first time. The 
abbreviations mentioned only once are not included in this list.
aa Amino acid
ALPL Tissue-non specific alkaline Phosphatase gene
ALPP Placental alkaline Phosphatase gene
Bp Base pairs
cDNA Complementary DNA
ddH20 Double-distilled water
DNA Deoxyribonucleic acid
dNTPs Deoxynucleoside triphosphate (A, C, G and T)
DTT Dithiothreitol
EAWS ESE Analyzer Web Server
EDTA Ethylenediamine tetra-acetic acid
ESE Exonic Splicing Enhancer
ESS Exonic Splicing Silencer
hnRNP Heterogenous ribonuclear protein
IPTG Isopropyl-P-d-thiogalactopyranoside
ISE Intronic Splicing Enhancer
ISS Intronic Splicing Silencer
kb Kilobase
Kcat catalytic rate constant
kDa Kilodalton
Km Michaelis constant
mRNA Messenger ribonucleic acid
N Nucleotide (A or C or G or T)
nt Nucleotides
PBS Phosphate buffer saline
PLAP Placental alkaline Phosphatase protein
pNPP p-Nitrophenylphosphate
RNA Ribonucleic acid
RT-PCR Reverse transcriptase polymerase chain reaction
9
snRNP Small nuclear ribonucleoprotein particles 
SR Arginine-serine rich protein
ss Splice site
TBE Tris-borate-EDTA (buffer)
TNAP Tissue-non specific alkaline Phosphatase protein
ABSTRACT
The process of pre-mRNA splicing involves the removal of intronic sequences from the 
pre-mRNA and it is directed by intronic cis acting elements know as the 5’ and 3’ splice 
sites that mark the boundaries of the exons. Over the two decades, however, it has become 
clear that exons encode for auxiliary splicing signals that either enhance or perturb their 
inclusion in the final mRNA product. It is possible that the evolution of mRNA sequences 
could be conditioned by the presence of these exonic cis-acting splicing regulatory elements 
and not mainly by the selection of optimal protein function.
To explore this hypothesis, I have investigated how the need for ESE influences the gene 
evolution of a paralogous gene family, specifically the human Alkaline Phosphatases 
(ALPs). In this work, I have identified in correspondence to a weak 3’splice site, two ESE 
sequences in the placental ALP exon 4, and demonstrate that the ESE are necessary for the 
exon inclusion in the mRNA due to the weak 3’splice sites. Furthermore, I show that they 
are absent in the corresponding exon of the non-tissue specific ALP transcript, specifically 
exon 5 that carries a strong 3’ splice site. Most importantly, the localization of the ESEs 
correspond to an area that in the paralogous non-tissue specific ALP gene differs in amino 
acid composition with respect, not only to the placental ALP where I mapped the ESEs but 
also to the other members of the family, where this area is well conserved. These amino 
acid changes may represent a possible evolutionary constraint on enzymatic activity, in 
keeping with this hypothesis, substituting the amino acids in the region of the ESE for those 
of the paralogous non-tissue specific ALP gene increases the enzymatic activity. Thus 
splicing-related constraints challenge the primacy of biochemical function in rates of 
protein evolution.
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1. INTRODUCTION
1.1 Overview of splicing
The initial primary transcript, the precursor-messenger RNA (pre-mRNA), in 
eukaryotes is synthesized by RNA polymerase II (Pol II), and before leaving the nucleus 
undergoes several modifications that can occur co- and post- transcriptionally. These tightly 
regulated steps begin in the nucleus with the chromatin decompaction that facilitates the 
recruitment of the Pol II to the transcriptional start site. Soon after Pol II initiates 
transcription, the nascent RNA is modified by the addition of a 7-methyl guanosine cap 
structure at its 5’ end that occurs co-transcriptionally, within only about 20-30 nucleotides 
(nt) of transcription. This cap serves initially to protect the new transcript from attack by 
nucleases and later serves as a binding site for proteins involved in export of the mature 
mRNA into the cytoplasm and its translation into protein (Lewis and Izaurralde, 1997). 
Coding sequences in the gene (exons) are interrupted by non-coding sequences (introns), 
which are removed by pre-mRNA splicing to generate mature transcripts (Gilbert, 1978). 
Over the past decade direct evidences have been shown that pre-mRNA can be spliced 
during its synthesis (Fong and Zhou, 2001; Komblihtt et al., 2004). A multi-protein 
complex machine called the spliceosome carries out this reaction (Staley and Guthrie, 
1998). Upon reaching the end of a gene, Pol II stops transcription and the newly 
synthesized RNA is cleaved and a poly(A) tail is added to the 3’end of the transcript 
(“polyadenylation”) (Proudfoot et al., 2002). The processes by which information is 
transferred from DNA to RNA and from RNA to protein are physically separated in 
eukaryotes by the nuclear membrane. Therefore, processed mRNAs must be transported 
from the nucleus to the cytoplasm before translation can occur (Fig. 1.1).
12
Thus, eukaryotic gene expression requires a careful orchestration of all the steps involved 
and some mechanisms are still unknown. Indeed, one of the fundamental issues in RNA 
splicing research is represented by understanding how the spliceosome can successfully 
define exons and introns in an ocean of similar sequences. Since its first description, 
researchers in this field have identified and characterized many fundamental elements and 
players capable of affecting the splicing process, both in a negative and positive manner. 
These elements range form the basic sequences that define the exon/intron boundaries to 
nucleosome positioning and epigenetic factors (de Almeida and Carmo-Fonseca, 2012).
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Figure 1.1 Schematic representation of the complex network during mRNA processing. 
The diagram illustrates as each step of gene expression is coupled one to another, from the 
chromatin decompaction that facilitate the recruitment of the Pol II enzymes to the 
transcriptional start site. Soon after Pol II initiates transcription, the nascent RNA is 
modified by the addition of a 7-methyl guanosine cap structure at its 5’ end. Coding 
sequences in the gene (exons) are often interrupted by non-coding sequences (introns), 
which are removed by pre-mRNA splicing to generate mature transcripts. Upon reaching 
the end of a gene, Pol II stops transcription and the newly synthesized RNA is cleaved and 
a poly(A) tail is added to the 3’end of the transcript (“polyadenylation”). Once an mRNA 
has been fully processed, it must be transported to the site of protein translation in the 
cytoplasm. Figure modified from Orphanides et al. (2002).
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1.2 Spliceosome complex formation
As mentioned the actual process of splicing is carried out by the spliceosome, one of 
the most complex macromolecular machines in the cell, characterized by highly dynamic 
associations and dissociations of several particles (Will and Luhrmann, 2011). The essential 
components have being characterised as five small ribonuclear proteins snRNPs U l, U2, 
U4, U5 and U6 that function in conjunction with over 200 non sn-RNP auxiliary proteins 
(de Almeida and Carmo-Fonseca, 2008; Hartmuth et al., 2002; Jurica et al., 2002). The 
assembly of the spliceosome has been characterized principally using in vitro systems 
where several distinct intermediates in an assembly pathway can be observed (Query et al., 
1995) (Fig. 1.2).
The basic steps of spliceosomal components interaction with pre-mRNA starts with 
Ul snRNP that base-pairs with the 5’ splice site (ss) and non-snRNP factors such as U2 
auxiliary factor (U2AF) which is a heterodimer that includes a 65 kDa subunit (U2AF65), a 
protein containing tandem RNA recognition motifs that binds tightly to the polypyrimidine 
tract, and a 35 kDa subunit (U2AF35) which binds the actual 3’ ss (Brow, 2002) and 
SF1/BBP (splicing factor 1/branch binding protein) that recognizes the branch point 
sequence. These factors, together with additional proteins, form a first discrete functional 
spliceosome complex called the E or commitment complex. The E complex bridges the 
intron and plays a crucial role in the initial recognition of the splice sites to be cleaved 
together. In a subsequent step, U2AF recruits the U2 snRNP, and an ATP dependent step 
allows the RNA portion of the U2 snRNP to base pair with a branch point and SFl/mBBP 
is displaced. This base pairing of the U2 snRNP with the branch point completes the A 
complex. After, ATP dependent recruitment of U4-U6-U5 tri-snRNPs to the 5’ss the B 
complex is formed. After the release of Ul and U4 and compositional rearrangments the 
complex is able to catalyze the first of the two transesterification steps of splicing described
15
below. After conformational rearrangements the C complex is formed, which catalyzes the 
second transesterification reactions on the splice sites (Konarska et al., 2006).
Figure 1.2. Spliceosome 
assembly. The spliceosome 
assembles onto the pre- 
mRNA in a stepwise 
manner. The E complex 
contains Ul snRNP bound 
to the 5’ splice site, SF1 
bound to the branch point, 
and U2AF65 and U2AF35 
bound to the pyrimidine 
tract and 3’ splice site AG, 
respectively. In the A 
complex, SF1 is replaced 
by U2 snRNP at the branch 
point. The U4/U6/U5 tri- 
snRNP then enters to form 
the B complex. Finally, a 
rearrangement occurs to 
form the catalytically active 
C complex, in which U2 
and U6 interact, and U6 
replaces Ul at the 5’ splice 
site. Figure modified from 
Hertel et al. (2005)
Pre-mRNA
A ^  y y y y y y y y y y y a c Q ^ Q
E Complex
A Complex
C Complex
U6snR NP
snRNP
snRNP U2 snRNP
U2snRNP
B Complex
U4/U6 °U5 tri-snRNP
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During the actual transesterification reactions, in the first step the 2’-hydroxil group 
of the adenosine at the branch site carries out a nucleophilic attack on the 5’ss, breaking the 
phosphodiester bond and forming the T -5’ linkage between the branch site and the 5’- 
terminal nucleotide of the intron. This reaction generates the splicing intermediates (free 
exon 1 and lariat-exon 2). In the second step the 3’ hydroxyl group of the exon 1 attacks at 
the 3’ splice site creating a new phosphodiester bond between exon 1 and exon 2 and a free 
intron released in form of “lariat” (Lamond, 1993; Moore and Sharp, 1993) (Fig. 1.3). After 
this second step, the mRNA is released, the snRNPs dissociate and than can take part in the 
next splicing reaction.
17
Step 1
E xon 1 I -° -P G U ----------A2’OH— AG-o-p E xon 2
m
Step 2
Lariat
E xon 1 — 3s OH
L anat i
— 3’O H  + E xon 1 r E xon 2
0  = 3’ oxygen o f exon 1 
0  = 2’ oxygen o f branch point A 
O = 3s oxygen o f intron
Figure 1.3. Schematic representation of sequential transesterification during splicing. In the 
first reaction, the ester bond between the 5' phosphorous of the intron and the 3' oxygen 
(red) of exon 1 is exchanged for an ester bond with the 2' oxygen (dark blue) of the branch- 
site A residue. In the second reaction, the ester bond between the 5' phosphorous of exon 2 
and the 3' oxygen (light blue) of the intron is exchanged for an ester bond with the 3' 
oxygen of exon 1, releasing the intron as a lariat structure and joining the two exons. 
Arrows show where the activated hydroxyl oxygens react with phosphorous atoms.
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1.3 Alternative splicing: where a common precursor pre- mRNA 
molecule can generate multiple mRNAs
As previously explained, the splicing reaction occurs in two transesterification steps
within a large spliceosome complex. Splicing can be either constitutive (when the exon in 
question always forms part of the mRNA) or alternative. During alternative splicing, the 
spliceosome assembly is altered so that a splice site is optionally used depending on the cell 
type, developmental stage or sex, resulting in the inclusion or exclusion of alternative exon 
sequences in the mature mRNA. Alternative splicing is therefore a process by which the 
exons of the RNA produced by transcription are reconnected in multiple different ways 
increasing greatly protein diversity.
Transcripts from a gene can undergo many different patterns of alternative splicing. Typical 
possibilities of alternative splicing are inclusion or skipping of one or more exons (cassette 
exons), shortening or lengthening of an exon by alternative 5’ and 3’ splice site usages, 
mutual exclusion of two or more exons, and retained introns. Different promoters and 
different polyadenylation sites may specify alternative 5’ and 3’ terminal exons, 
respectively. Combinations of different basic types can form more complex alternative 
splicing patterns (Fig. 1.4).
Estimates of how commonly alternative splicing occurs in human protein coding genes 
have increased over the years, from an initial 5 % to more than 95 % (Calarco et al., 2011; 
Sharp, 1994). Recent studies have suggested that alternative splicing is nearly ubiquitous in 
human transcripts and is frequently controlled in a tissue specific manner (Pan et al., 2004; 
Wang et al., 2008). The consequences of alternative splicing include altered mRNA 
stability or subcellular localization and the addition or deletion of specific protein coding 
sequences. These mechanisms of alternative splicing are so tightly controlled that even 
subtle defects in alternative splicing factors or aberrant inclusion of alternative exon can 
result in genetic diseases (Faustino and Cooper, 2003; Kashima and Manley, 2003; 
Licatalosi and Darnell, 2006).
19
Cassette Exon
Mutually Exclusive Exons
Intron Retention
Alternative 5 ’ or 3 ’Splice Sites
Alternative Promoters
PI P2
Alternative Splicing 
and Polyadenylation
AAA...
Figure 1.4. Modes of alternative splicing. Typical types of alternative splicing are inclusion 
or skipping of one or more exons (cassette exons), mutual exclusion of two or more exons, 
retained introns and shortening or lengthening of an exon by alternative 5’ and 3’ splice 
site. Different promoters (P) and different polyadenylation sites may specify alternative 5’ 
and 3’ terminal exons, respectively. In these graphics, exons are represented by boxes and 
introns by lines. Exon regions included in the messages by alternative splicing are colored 
while constitutive exons are shown in green. Promoters are indicated with arrows and 
polyadenylation sites with AAAA.
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1.4 Donor and Acceptor splice site sequence
Discrimination between exon and intron sequences is a complex task for the splicing 
machinery. In general, it is directed by the presence of specific consensus sequences at the 
exon-intron junctions (Fig. 1.5).
The 5’ ss motif (donor site) marks the exon/intron junction at the 5' end of the intron and in 
higher eukaryotes consists of nine partially conserved nucleotides, YAG/GURAGU (where 
Y is a pyrimidine, R is A or G and the slash the exon-intron boundary), at the exon-intron 
junction, spanning from position -3 to +6. This consensus sequence is however highly 
degenerate with only the underlined GU dinucleotide being universally conserved 
(Langford et al., 1984; Sun and Chasin, 2000) (Fig 1.5). Recognition of the 5’ss involves a 
nearly perfect Watson-Crick base pairing with the Ul snRNA that guides the early 
assembly of the spliceosome machinery upon the intron (Horowitz and Krainer, 1994). 
Indeed several studies have shown that the introduction of mutations that improve the 
match of weak splice sites to the consensus can lead to the constitutive recognition of 
alternatively skipped exons (Del Gatto et al., 1997; Huh and Hynes, 1993; Muro et al.,
1998). The extent of sequence complementarity of the 5’ss to the Ul snRNA is used to 
calculate the strength of the ss with 5’ss that have a high complementarity with U l snRNP 
shown to splice more efficiently than those with low complementarity (Roca et al., 2005). 
The possibility of attribute strength to the splice site, described by a consensus sequence, 
has being the focus of many studies principally based on position weight matrices that are 
calculated from collections of splice sites (Senapathy et al., 1990; Shapiro and Senapathy, 
1987). Today, a number of bioinformatics resources, albeit with slightly different modes of 
calculation of 5’ strength are available, the more utilized of which are listed in Table 1.1. 
The 3’ss (acceptor site) is even more loosely defined than the 5’ss and is composed by three 
elements: the branch point sequence (BPS), polypyrimidine tract (PPT) and the actual 3’ss 
(intron/exon junction) (Fig. 1.5).
2N
The branch point sequence (BPS) consists of the highly degenerated sequence YNYTRAY 
(where Y is C or T) containing the branch point adenosine that is involved in the first step 
of splicing reaction (A underlined above) (Query et al., 1994). Most branch points have 
been mapped within 18-40 nt of the 3’ss (Reed and Maniatis, 1988).
The polypyrimidine tract (PPT) is a run of pyrimidines (Y(n)-eight bases in the average 
intron), located between the branch site and the terminal AG at the intron/exon junction.
The actual 3 ’ss defines the 3’ border of the intron, just downstream to the PPT. This site is 
characterised by the short YAG/G sequence (Y denotes pyrimidines; the slash indicates the 
intron-exon boundary and the underlined nucleotides are conserved).
Also the 3’ss is described by consensus sequence. In general, the extent of the 
polypyrimidine tract defines the strength of the 3’ splice sites: long polypyrimidine tracts 
insure high affinity binding sites for spliceosomal components and promote efficient exon 
recognition (Reed, 1989). Commonly used programs to predict the 3’ss strength are listed 
in Table 1.1.
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Figure 1.5. Schematic representation of mammalian exon-intron boundaries and consensus 
sequences for 5’ and 3’ splice sites and branch point. The two exons and the intron are 
indicated. Poly (Y) tract means region reach in pyrimidines. The universally conserved 
nucleotides are the dinucleotide cores of the 5’ and 3’ splice sites GU and AG respectively 
together with the branch point (A).
Some deviations from the canonical variants of splice signals are known to exist. As stated 
the vast majority of spliceosomal introns contain |GT at the donor splice site and AG| at the 
acceptor splice site. However, a distinct class of rare introns has been recognized on the 
basis of their unusual terminal dinucleotides: these introns contain |AT at the donor splice 
site and AC| at the acceptor splice site (Hall and Padgett, 1994; Jackson, 1991). Introns of 
this class are excised by a distinct, so-called minor or U12 spliceosome, which contains 
several specific, low-abundance snRNPs. It has been subsequently shown that some |GT- 
AG| introns are also removed by the U12 spliceosome (Dietrich et al., 1997).
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Donor, 
acceptor site 
prediction
Web address Role Reference
a) MaxEntScan http://genes.rn
it.edu/burgela
b/maxent/Xma
xentscan_scor
eseq.html
Scores 5’ and 3’ss 
based on the 
maximum entropy 
principle (MEP).
(Yeo and Burge, 
2004)
b) NNSplice http://www.fr
uitfly.org/seq_
tools/splice.ht
ml
Scores potential 
splice sites s based 
on a generalized 
Hidden Markov 
Model (GHMM)
(Reese et al., 1997)
c) NetGene2 http://www.cb
s.dtu.dk/servic
es/NetGene2/
Prediction of 
transition regions 
between introns and 
exons regulates a 
cutoff level for 
splice site 
assignment
(Brunak et al., 1991)
d) Cryp-Skip http://cryp-
skip.img.cas.c
zJ
Detection of cryptic 
splice sites
(Divina et al., 2009)
e) GeneSplicer http://www.cb
cb.umd.edu/so
ftware/genespl
icer/
Prediction of splice 
sites based on 
maximal 
dependence 
decomposition 
(MDD) and 
Markov (MM) 
models
(Pertea et al., 2001)
Table N.N. Programs used to analyze splice sites.
N.4.N Relative strength and cooperation between signals
Several studies have disclosed the synergy existing either between the 5’ and 3’ 
splice sites or between the polypyrimidine tract and the branch point. It has been 
demonstrated that strong sequence within the 5’ splice site of an exon can promote the use 
of its own 3’ splice site (Nasim et al., 1990). On the other hand, sequences, upstream the 3’ 
splice site of an exon can facilitate the use of a downstream 5’ splice site (Tsukahara et al., 
1994).
The polypyrimidine tract determines the location of the branch point sequence and 
indirectly the 3’ss (that is usually the first AG downstream the branch point). It has also 
been shown that a strong polypyrimidine tract can partially balance a weak branch point 
sequence. Likewise, a strong branch point site can partially balance a weak polypyrimidine 
tract (Buvoli et al., 1997). Finally, also the distance between the branch point sequence and 
the pyrimidine tract is critical for efficient lariat formation (Gattoni et al., 1988).
N.5 Exon/Intron Architecture
In addiction to splice site sequences, the exon/intron architecture in pre-mRNA is 
important for efficient splice site recognition (Deutsch and Long, 1999).
The architecture of exon and introns may be different across eukaryotic organisms. In 
general, vertebrate genes are characterized by short exons (average size of 170 nt.) 
separated by considerably longer introns (Sakharkar et al., 2005; Zhang, 1998). 
Interestingly, experiments aimed to investigate the influence of exon and intron sizes in pre- 
mRNA processing showed that spliceosome formation is strongly inhibited if exons lengths 
are expanded artificially to over 300 nt. However, some exceptionally long exons exist, and 
in these cases it has been observed that inclusion still occurs efficiently if  the flanking 
introns are small (Sterner et al., 1996).
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The variable size of exon-intron units suggested that two ways of recognizing intron and 
exons exist: intron and exon definition models (Fig. 1.6). Basically, when exons are small 
and introns are long the splicing machinery is more likely to identify and assemble across 
the small exon than across the large intron (Robberson et al., 1990). This model based on 
pairing between the splice sites across an exon that is called "exon definition model” (Fig. 
1.6A) (Berget, 1995). In the alternative model, also known as the “intron definition” model, 
splice sites are initially paired across small introns rather than exons permitting splice site 
recognition within the same intronic splicing unit (Fig. 1.6B) (Berget, 1995; Lang and 
Spritz, 1983).
Recently, the intronic length above which exon definition becomes predominant has been 
estimated to be approximately 200-250 nucleotides (Fox-Walsh et al., 2005). On a practical 
level, however, there is no difference in spliceosomal complex assembly over exons or 
introns and both exon definition and intron definition may occur in different parts of the 
same pre-mRNA. At present, the transition from cross-exon to cross-intron interaction is 
still poorly understood and may often involve the action of additional cis-acting sequences 
to help the spliceosome to home in on the correct splice sites (Ram and Ast, 2007; Sharma 
et al., 2008).
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Figure 1.6. Exon and Intron definition models. (A) When the intron is small (less than 
about 250 nt) the spliceosome can recognize the splice sites that will be pared across the 
intron, referring to the “intron definition model” of splice site recognition. (B) When 
introns are large (greater than about 250 nt), splice site communication occurs across exons, 
referring to the “exon definition model” of splice site recognition.
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N.6 Auxiliary splicing regulatory element
Although, the aforementioned information makes a strong case that the splice sites 
and exon/intron architecture are important for activating pre-mRNA splicing, these factors 
are not the only players.
It is well known that many potential splice sites are in fact present along all pre-mRNAs but 
the vast majority of these sequences, known as pseudosplice sites are never selected for 
splicing. For example, a computer search for potential splice sites in the 42kb human hprt 
(hypoxantine phospho-ribose transferase) gene, composed of nine exons and eight introns, 
found the eight real 5'ss but also found over 100 5' splice sites that were never recognized 
by the splicing machinery. The case was even more extreme for the 3'ss where 683 pseudo­
sites were found with higher scores than the lowest scoring real site (Sun and Chasin, 
2MMM).
This degeneration of the splicing code means that mammalian genes are full of apparently 
viable 5' ss and 3' ss consensus sequences but only a minority specifies for a "real" exon, 
thus the more arduous tasks of the spliceosome is to identify the bona fide splice sites from 
the numerous pseudo sites found in any pre-mRNA transcript. Certainly, the relative 
strength of the splice sites plays a major role in determining whether the fundamental 
snRNP factors will be able to bind or not (Roca et al., 2005). However, although necessary, 
the 5’ and 3’ splice sites are by no means sufficient to define the exon/intron junctions. 
Evidence for additional splicing regulatory elements (SRE) came about as early as 1987, 
with the observation that exonic sequences away from the 5’ and 3’ splice sites were 
involved in the definition of alternative splicing exons (Mardon et al., 1987).
Today far from being exceptional, the majority of pre-mRNA molecules are known to 
contain a myriad of auxiliary splicing cis-acting regulatory elements that either enhance or 
inhibit exon-intron recognition.
These SREs reinforce the limited information in the splice sites and depending on their
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location and their function, these elements are referred as exonic splicing enhancers (ESE) 
or silencers (ESS) and intronic splicing enhancers (ISE) or silencers (ISS). Enhancers and 
silencers are involved in both constitutive and alternative splicing and in most cases they 
lack a well defined consensus sequence (Baralle and Baralle, 2005; Buratti et al., 2006; 
Cartegni et al., 2002).
These elements are not always unequivocally defined and their functions may overlap. In 
fact, in some systems it may be more appropriate to talk about composite exonic regulatory 
elements of splicing (CERES) as has been described for CFTR exons 9 and 12 (Pagani et 
al., 2003c; Pagani et al., 2000).
Ultimately, the combinatory effect of all the cis- acting elements located in proximity or 
within an exon affects the spliceosome assembly, promoting or inhibiting exon inclusion in 
the final mRNA (Matlin et al., 2005).
N.6.N Enhancer Elements
Although originally discovered in regulated exons, ESEs are today also known to be 
components of constitutively spliced exons (Mayeda et al., 1999; Schaal and Maniatis,
1999). Regarding their mode of action, ESEs generally assist early spliceosomal complex 
formation by interacting with components of the splicing machinery that make up 
previously described the E complex (Reed, 1996).
ESEs have been the subject of many studies and most, but not all, are known to be 
recognised by members of the SR protein family of splicing factors (Blencowe, 2000; 
Coulter et al., 1997; Graveley, 2000; Manley and Tacke, 1996; Tacke and Manley, 1999). It 
should be noted that there are many exceptions for example, classical SR proteins have also 
been described to be involved in splicing repression in some cases (Kanopka et al., 1996; 
Pagani et al., 2000).
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The SR proteins have a common domain structure of one or two RNA recognition motif 
(RRM) followed by an RS domain containing repeated arginine/serine dipeptides, which 
can be highly phosphorylated. This phosphorylation modulates protein-protein interaction, 
that serves as a bridge between the 5’ and 3’ splice sites across the introns and across the 
exons and/or between enhancers and adjacent splice site, within the spliceosome (Black, 
2003; Caceres et al., 1998; Ram and Ast, 2007). The structural organization of SR proteins 
suggests a model for their function. The RRM mediates sequence-specific binding to the 
mRNA, whereas the RS domain seems to be involved mainly in protein-protein interactions 
(Cartegni et al., 2002; Graveley, 2000).
Two non-exclusive models have been proposed to explain the role of SR protein in pre- 
mRNA splicing (Fig. 1.7). One model is supported by the observation that ESE-dependent 
splicing, requires protein-protein interactions mediated by SR proteins (Hertel and 
Maniatis, 1999). Through this interaction, the splicing factor U2AF is thought to be 
recruited onto a suboptimal, upstream 3’splice site and stimulate spliceosome assembly. 
The recruitment of U2AF, seems to be important, especially in those cases in which 
recognition of weak pyrimidine tract is a rate-limiting step in splicing reaction (Graveley et 
al., 2001)(Fig. 1.7A).
The second model proposes that a SR protein, bound to an ESE, can antagonize the 
negative effect of a juxtaposed silencer element (Cartegni et al., 2002; Sanford et al., 2005). 
However, in some cases SR proteins can act in a negative fashion. The negative effect on 
splicing can be mediated by the binding to an intronic sequence (ISS) (Buratti et al., 2007; 
Ibrahim el et al., 2005) or by the inhibitory property of the protein itself, as reported for 
SRp38 and SRp86 (Barnard et al., 2002) (Fig. 1.7B).
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Figure 1.7. Models of SR protein action in exonic-splicing-enhancer-dependent splicing. 
(A) RS-domain-dependent mechanism. An SR protein binds to an exonic splicing enhancer 
(ESE) through its RNA-recognition motifs (RRM) and contacts the splicing factor U2AF35 
and/or U1-70K at the adjacent splice sites through its RS domain. U2AF65 binds to the 
polypyrimidine (Y) tract, which here is interrupted by purines and is therefore part of a 
weak 3' splice site. U2AF65 also promotes binding of U2 snRNP to the branch site. The U1 
snRNP particle binds to the upstream and downstream 5' splice sites through base paring of 
the U1 snRNA. The three sets of splicing-factor-pre-mRNA interactions (U2AF-3’ splice 
site, U1 snRNP-5' splice site and SR protein-ESE) are strengthened by the protein-protein 
interactions (black arrows) that are mediated by the RS domain. (B) RS-domain- 
independent mechanism. Here, the main function of the SR protein that is bound to an ESE 
is to antagonize the negative effect on splicing of an inhibitory protein that is bound to a 
juxtaposed exonic splicing silencer (ESS). The SR protein is shown without its RS domain, 
although this domain is normally present and might still promote U2AF binding, or other 
domains might be involved in protein-protein interactions. Inhibitory interactions are 
shown (red), as is a putative stimulatory interaction (double-headed arrow). These models 
are not mutually exclusive, and the splicing of some introns might involve a combination of 
these mechanisms. Figure adapted from Cartegni et al. (2002).
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CA-acting enhancer regulatory elements in the intronic sequences have being studied 
to a lesser extent, however ISE do indeed exist and a number of examples have been 
studied. One well characterized ISE element is the triplet (GGG) which often occurs in 
clusters and can enhance recognition of adjacent 5’ or 3’ splice sites or the intronic (CA) 
repeats that in several cases can enhance splicing of upstream exons (Hui and Bindereif, 
2005; McCullough and Berget, 1997).
1.6.2 Silencer Elements
In addition to sequences that promote exon inclusion, there are sequences that inhibit 
splicing, so called exonic or intronic splicing silencers. The silencers are less well 
characterized: they can be purine or pyrimidine-rich and bind a diverse array of proteins 
which have not been characterized to the same extent as the enhancers, however 
heterogeneous ribonuclear proteins (hnRNPs) have been generally implicated in interactions 
with these elements and in particular, ISS are usually recognized by the polypyrimidine 
track binding protein (PTB; also known as hnRNPI) (Fairbrother and Chasin, 2000; Garcia- 
Bianco et al., 1989). Several mechanisms have been proposed for ESS- or ISS-mediated 
splicing repression, indeed, hnRNP-bound splicing silencer have been shown to repress 
spliceosomal assembly through multimerization along exons (Zhu et al., 2001), blocking the 
recruitment of snRNPs (House and Lynch, 2006), or by looping out the exon (Martinez- 
Contreras et al., 2006).
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1.6.3 Bioinformatic analysis of SRE
Although these additional elements are often conserved between species, highly 
degenerate sequence motifs characterize these sequences, making their identification 
difficult.
Due to the importance of SRE(s) a number of both experimental and computational
approaches have also been developed in order to identify the auxiliary splicing regulatory
motifs that regulate exon inclusion. The result of these studies led to the development of
computational methods that predict splicing regulatory sequences and their binding
partners. The experimental approaches have included classical SELEX experiments,
functional SELEX, (Buratti and Baralle, 2005; Cartegni et al., 2002; Coulter et al., 1997) in
vitro splicing assay (Smith et al., 2006) and in vivo screening for regulatory elements
(Wang et al., 2004). In particular, the classical SELEX approach has been used for a variety
of splicing factors, with a particular emphasis towards the splicing factors that up- or down
regulate exonic inclusion. However, sequences belonging to naturally occurring enhancer or
silencer elements do not always correspond to the optimal binding sites that have been
identified using the selection techniques. Therefore, the functional SELEX approach has
been introduced, combining the splicing functionality and protein-RNA binding efficiency.
Exonic splicing enhancer (ESE) sequences can be functionally investigated by coupling the
SELEX basic methodology with an in vitro splicing RNA template. To obtain selection
specificity for a specific splicing factor, the splicing reaction can be performed in a depleted
nuclear extract that can drive the splicing process only if complemented by a recombinant
splicing factor of interest. These functional experiments have enabled the elaboration of
binding matrices, which can then be used to search for potential SR-binding motifs in any
RNA sequence of interest using a web-based application, ESE-Finder
fhttp://rulai.cshl.edu/tools/ESE/I (Cartegni et al., 2003). This has resulted in the
identification of high-affinity binding sites for four SR proteins: SF2/ASF, SC35, SRp40
and SRp55. These binding sites consist of purine-rich sequences known to function as a
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splicing enhancer.
In addition to the ESE-finder application, another web-based application for predicting the 
occurrence of enhancer motifs (but based on the statistical analysis of exonic sequences 
rather than selection procedures) RESCUE (relative enhancer and silencer classification by 
unanimous enrichment)-ESE (http://genes.mit.edu/burgelab/rescue-ese), was tested 
(Fairbrother et al., 2004b). RESCUE-ESE looks for hexanucleotides that are significantly 
enriched in exons as opposed to introns and also more abundant in exons with weak (non­
consensus) splice sites than in exons with strong splice sites. This approach identified 238 
hexanucleotides, and a sample of them was successfully validated using minigene system 
for testing enhancer activity.
Although promising, this web-based approaches show a variable degree of reliability and 
high false positive rate, hence, at present there is no substitute for functional experiments to 
validate splicing predictions.
1.7 Combinatorial Mechanism
In higher eukaryotes, the gene complexity and the relatively low level of splice site 
conservation, make the precision of the splicing machinery in recognizing and pairing 
splice sites impressive.
Over the last few years, it has become increasingly clear that to reach this outcome, splice 
site selection has evolved to depend on multiple parameters such as splice site strength, the 
exon/intron architecture and RNA secondary structures. The sum of contributions from 
each of these parameters is necessary to control the generation of constitutive and 
alternatively spliced mRNA molecules (Hertel, 2008).
An example of combinatorial splicing regulation is the SRC tyrosine kinase gene in which a 
cassette exon N1 is included in neurons, but skipped in non-neuronal cells (Levy et al., 
1987). The exon N1 (18 nt) is located between exon 3 and 4 and in non-neuronal cells, exon 
N1 is skipped to generate c-src transcript. PTB binds cooperatively to sequences on both
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sites of the N1 exon. As a result, exon 4 splices to exon 3. In neuronal cells, N1 is included 
between exon 3 and 4 to form the n-src transcript. In this case PTB is replaced by less 
repressive neuronal PTB an enhancer complex assembles on the downstream control 
sequence resulting in the inclusion of N1 exon in the mRNA (Black, 2003; Modafferi and 
Black, 1997). Thus, in this as in most cases, the decision to splice is due to a balance of 
multiple positive and negative inputs.
1.8 Protein evolution: An Overview
Several important hypotheses have been proposed so far to determine the main 
players acting on protein evolution (Pal et al., 2006).
A landmark study from Zuckerkandl and Pauling (Zuckerkandl and Pauling, 1965) 
suggested that there is a uniform rate of amino acid changes, named molecular clock, 
among species. This observation was the basis for the development of the neutral theory of 
molecular evolution. The neutral theory (Kimura, 1983) suggested that advantageous 
mutations occur so infrequently that they do not significantly contribute to the rate of 
molecular evolution and consequently most amino acid substitutions are neutral and fixed 
by random genetic drift with a constant substitution rate.
In the 1970s, the sequencing of many proteins from diverse species provided opportunities 
to examine the nature of the protein clock. By 1971, it was shown that the rate of molecular 
evolution was constant only for a particular protein but it was vastly different among 
different proteins. It was also suggested that the surface residues of a specific protein could 
be constrained by the protein’s interactions with other proteins, therefore some portions of 
the surface of certain proteins seemed to have higher functional constraint than others. For 
example, fibrinopeptides have little functional constraint and evolve very fast; instead 
cytochrome c has high functional constraints and evolves very slowly (Dickerson, 1971) In 
this case assuming that functionally important amino acids remain essentially unchanged in
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the evolutionary process but others can change with neutral rate, the rate of amino acid 
substitution (r) was expressed by r = jv  w here/is the proportion of neutral mutations and v 
is the mutation rate per site. This predicts that less important proteins should evolve at 
faster rates (higher r) because f  should be greater for less important proteins.
In the following years Zuckerkandl also indicated that the rate of evolution is proportional 
to the density of protein functional domains. In the “functional density hypothesis” it was 
suggested that the selective constraint should be proportional to the number of residues 
involved in its function and that the domain architecture of the protein should be untouched 
to avoid selective pressure (Zuckerkandl, 1976). The functional density (F) can be 
expressed as F = ns /  N  where ns is the number residues involved in specific function and 
cannot be easily substituted and N  is the total number of sites in the protein. This formula 
should reflect the ratio of constrained to neutral amino acids for a given protein, hence, it 
should be proportional to the rate of sequence evolution. The measurement of functional 
density remained tricky because residues may contribute to protein function in 
unpredictable ways. Many recent surveys have analyzed other measures that may represent 
functional density, such as expression level and dispensability. Indeed, Wilson et al. 
proposed that two proteins subject to the same level of functional constraint, but differing in 
their dispensability, would evolve at different rates. Thus, essential genes (knockouts of 
which are lethal or infertile) should evolve slower than non-essential genes (knockouts of 
which are viable and fertile) (Wilson et al., 1977).
Most recently, a study has led to the “fitness density hypothesis” in which the rate of 
evolution was considered as a measure of the change in fitness of the mutant protein 
(relative to the wild type molecule). Consequently, it has been shown that non-essential 
protein have higher rate of evolution since they can accumulate mutations without resulting 
in a deleterious effect on the fitness. Conversely, essential proteins having stronger fitness 
effect are subjected to higher selective pressure, reducing the possibility to accumulate 
deleterious mutations (Hirsh and Fraser, 2001).
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1.8.1 Codon based model of protein evolution
Many different mathematical models have been developed for identifying the way 
in which selection occurs, one of the most used is a codon substitution model. Mutation rate 
of protein coding sequences treat the codon as the unit of evolution and distinguish between 
synonymous and nonsynonymous rates of evolution. Synonymous mutations yield a 
different codon without changing the encoded amino acid and therefore do not affect the 
protein sequence. Nonsynonymous mutations, on the other hand, result in replacement of 
one amino acid with another. This distinction enables the calculation of two substitution 
rates: Ks, the number of synonymous substitutions per synonymous site and Ka, the number 
of nonsynonymous substitutions per nonsynonymous site (Goldman and Yang, 1994).
By distinguishing between Ks and Ka it is possible to draw inferences regarding the nature 
of the selection operating on the protein-coding sequence. In particular, the ratio of these 
rates (Ka/Ks) is commonly used to estimate co (the amino acid selection pressure) corrected 
for 7i (the background nucleotide mutation rate). This follows from the fact that, because 
synonymous changes are silent at the protein level, synonymous sites are typically regarded 
as neutrally evolving. Therefore, the synonymous rate is dependent on the nucleotide 
mutation rate, n and not on amino acid selection pressure, co. Nonsynonymous sites, on the 
other hand, evolve at a rate determined by both these processes.
In a neutrally evolving protein-coding sequence nonsynonymous mutations are as likely to 
be fixed as synonymous mutations (i.e., Ka/Ks is expected to equal one). This fact as led to 
the common use of the ratio Ka/Ks to estimate the nature and magnitude of different types 
of amino acid selection pressure. Values of Ka/Ks < 1 indicate the operation of purifying 
selection in causing a reduction in the fixation rate of amino acid changes that are 
deleterious relative to the silent synonymous rate. Positive selection for beneficial amino 
acid changes is frequently inferred when Ka/Ks > 1 (Hurst, 2002).
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1.8.2 Splicing and the evolution of proteins in mammalian proteins
The higher variability of rates in multicellular organisms such as mammals could be
generally due to different factors. First, the small size of population can influence the
efficiency of selection against deleterious mutations. Second, the organization in tissue and
organs in mammals is likely to be associated with selective constraints indeed, early studies
of the impact of expression breadth on protein evolution in mammals have shown that the
rate of amino acid substitution depends on the tissue in which proteins are expressed
(Hughes, 1997; Kuma et al., 1995) and, also, that broadly expressed proteins are more
conserved than tissue-specific one. Therefore, the slow evolution of a ubiquitously
expressed protein could be due to an increase in the functional density of a sequence
resulting from the dual requirement that the protein should function under a wide range of
conditions where it encounters a wide range of molecular interaction partners.
Another important factor affecting the rate of evolution of mammalian proteins is the
genome heterogeneity that produces the variation of synonymous substitution rate between
mammalian genes (Wolfe et al., 1989). Although, Ka/Ks ratio has been widely used to
measure the selective pressure on amino acids based on nucleotide mutations causing amino
acid changes of the encoding genes (Yang and Nielsen, 2000) this ratio often produces
ambiguous results due to the selection acting also on nucleotide mutation that do not cause
amino acidic changes (Hurst and Pal, 2001). For example, alternative spliced exons show
higher Ka/Ks ratio in sequence comparison indicating the importance of local segments like
SREs of the gene for selection (Xing and Lee, 2005a) (see sectionl.8.3).
Several bioinformatics analyses have confirmed that the need to preserve information
necessary for intron removal (e.g., exonic splicing enhancer) represent a strong force
operating on protein evolution in multicellular organisms (Wamecke et al., 2008). In
particular, the presence of splicing enhancers has been found to influence the usage of
synonymous codon near the splice sites. Indeed it has been documented that codons
preferred in ESE are recurrent near intron-exon boundaries (Berget, 1995). Willie and
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Majewski have evidenced that although both synonymous triplets GAA and GAG encode 
for the glutamic acid, have different usage in humans, GAA triplet represents the most 
common codon in exonic splicing enhancers and is also most frequently found near the 
splice site because of its role in promoting splicing. (Willie and Majewski, 2004). 
Conversely, a bioinformatic study showed that the AAG codon (lysine), even though it is 
abundant in ESE, exhibits a decrease frequency near the 5’end of the exon. This results 
have been explained with cryptic splice site avoidance theory in which Eskesen et al. have 
hypothesized that because the 3’ ends of introns typically terminate AG, exons should avoid 
using this nucleotide at the 5’ end to minimise the chance of deleterious aberrant splice 
forms. They also found some evidences also for GT avoidance at exonic 3’ends. (Chamary 
and Hurst, 2005; Eskesen et al., 2004).
More generally, analysis of the distribution of SNPs in human exons showed a decreased 
density near the 5’ and 3’ ends to preserve a correct recognition of the splice sites 
(Majewski and Ott, 2002). Additionally, RESCUE-ESE data set distribution showed an 
inverse trend compared with SNP density, with an increased concentration in vicinity of 
exon boundaries providing evidence that there is a purifying selection against mutations 
that affect ESE with lower rate of Ks than in non-ESE sequence.(Carlini and Genut, 2006; 
Fairbrother et al., 2004a) (Parmley et al., 2006). These bioinformatics studies are in 
accordance with in-depth analysis of genes that demonstrated that synonymous changes 
couldn’t evolve freely, because they can compromise correct splicing (Baralle et al., 2006; 
Pagani et al., 2005; Raponi et al., 2007).
Since these studies have challenged the neutrality of Ks, Ke et al. have introduced the rate
of intronic substitution (Ki) to estimate the neutral mutation rate. Using a genomic
comparative approach between human, chimpanzee and macaque, they have observed: (1)
lower Ks than Ki, supporting the role of RNA beyond protein coding; (2) the avoidance of
mutations that disrupt predicted ESE or create ESS and that synonymous substitution in
constitutive exon tend to create enhancer and eliminate silencer sequences; (3) when
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splicing efficiency tend to decrease in one species due for example to the weakening of 
splice site consensus sequence, there is a tendency to compensate this negative event with 
predicted ESE gain or ESS losses. These results supported the hypothesis of a purifying 
selection that acts to preserve these splicing-promoting sequences and a positive selection 
for their formation. It has been suggested that this positive selection might be the result of 
splicing-positive events compensating for splicing-negative events as well as for mutations 
that weaken splice-site sequences (Ke et al., 2008). Thus, based on the splicing 
compensation model of exon evolution, the splicing elements seem coevolve in a way that 
preserves overall exon strength, allowing specific elements to substitute for loss or 
weakening of others (Xiao et al., 2007). In line with this proposed model, a recent 
bioinformatics survey by Parmley et al. suggested that the selection acts not only on the 
synonymous codon choice near intron-exon junction, but also the majority of amino acids 
show skewed usage because of their involvement in splicing. The authors have also 
reported that ESEs leave an imprint on the amino acid composition of proteins. In fact, 
some amino acids, such as lysine (K) and isoleucine (I), are strongly preferred near 
boundaries whereas others, such as proline (P) and alanine (A), are significantly avoided 
due to the effect on splicing definition at the nucleotide level (Parmley et al., 2007).
1.8.3 Alternative splicing and evolution
Evolutionary studies, which have revealed the formation of de novo alternative 
exons and the evolution of exon-intron architecture, highlight the importance of alternative 
splicing in the diversification of the transcriptome, especially in humans.
Alternative splicing may, therefore, be a mechanism that enables evolution to experiment 
with newly created exons. The obvious correspondence with gene duplication was made 
explicit by a study documenting differences in gene structure between human and mouse 
orthologs (Modrek and Lee, 2003). Modrek and Lee analyzed a set of 9,434 orthologous 
genes in human and mouse. This work introduces an additional distinction within
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alternative exons: ‘major form” if the exon appears in at least 50% of the transcripts and 
“ minor form” otherwise.
They also introduced the term “internal paralog” to describe a “minor-form transcript” 
whose alternative exons are generally not conserved between human and mouse. This 
minor form is free of selective constraint thus allowing it to accumulate changes more 
rapidly. The major-form of alternative exons are much more conserved between human and 
mouse. Modrek and Lee demonstrated that alternative splicing is likely to have facilitated 
many of the changes that have occurred in the structure of genes since the human/mouse 
divergence. This was illustrated by the finding that species-specific exons are 10 times 
more likely to be alternatively spliced than conserved exons. Notably, this facilitation is 
dependent on the low frequency incorporation of these species-specific exons into 
transcripts. Alternatively spliced exons specific to human or mouse are nearly eight times 
more likely to be spliced at low frequencies (i.e., as the minor form) than alternative exons 
conserved between these mammals (Modrek and Lee, 2003). It is this low-frequency 
expression, by alternative splicing, of species-specific “internal paralogs” that is likely to 
protect newly formed exons from selection while ensuring that the gene’s ancestral function 
is not compromised.
Evidence is emerging for the existence of two contrasting selective pressures operating on 
alternatively spliced exons.
On the one hand, alternative splicing is associated with an apparent relaxation of negative 
selection. There is also evidence that purifying selection on amino acid changes (as 
measured by Ka /Ks) is up to seven-fold weaker in alternatively spliced exons (Xing and 
Lee, 2005b).
On the other hand, alternative splicing is also associated with an increased selective
constraint. Alternatively spliced exons are observed to be under stronger selection to
preserve reading frame (Resch et al., 2004) and to have fewer single nucleotide
polymorphisms (Yeo et al., 2005). Strikingly, a more than six-fold reduction in
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synonymous site divergence is seen among minor-form exons compared to constitutive 
exons (Xing and Lee, 2005a). The most likely explanation for the strong selective pressure 
on synonymous sites in alternative exons relates to the preservation of splicing regulatory 
motifs. Consistent with these findings the presumed neutrality of synonymous mutations 
has been challenged because of the presence of splicing regulatory elements overlapping 
with the amino acid code (Pagani and Baralle, 2004).
1.9 Impact of gene duplication on rates of molecular evolution
The duplication of single genes can occur by DNA-based tandem duplication and 
duplicative transposition. However, some duplication events do not generate perfect copies 
of their progenitor. The significance of gene duplication to genome evolution is estimated 
by the high birth rate of duplicated genes and frequently is a source for evolutionary 
innovation (Lynch and Conery, 2000). However, there is also a high frequency of gene 
duplicates lost from the genome.
1.9.1 Different mechanisms for paralogous genes preservation
Although the life of most gene duplicates is generally short there are several 
mechanisms that increase the survival chances of a newly formed gene duplicate.
The frequent loss of gene duplicates is consistent with Ohno’s classical model under which 
gene duplication creates two paralogous genes that are functionally redundant (Ohno, 
1970). This redundancy implies that one of the paralogs could evolve free from selective 
constraints. Under Ohno’s model the ultimate fate of this unconstrained paralog is 
determined by the neutral accumulation of mutations that were previously forbidden by 
selection. Given the abundance of degenerative mutations, the most likely event is the 
fixation of a null allele that results in the nonfunctionalization and ultimate loss of the gene
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duplicate. According to the classical model the only way to survive for a duplicate gene is 
the creation of a new function by the rare fixation of beneficial mutations. This process is 
referred to as neo-functionalization and can occur by the fixation of mutations in the 
duplicate gene’s protein-coding or regulatory sequences. A characteristic of the neo- 
functionalization mechanism is that the survival of a newly formed gene duplicate is 
guaranteed by its gain of a novel function that differentiates it both from its duplicate and 
ancestral copy.
An alternative, more recently described, model proposes that gene duplicates can be 
retained without functional innovation and adaptation. The sub-functionalization model 
(Force et al., 1999) provides a neutral explanation for the retention of duplicate copies of a 
multifunctional gene by degenerative mutations that lead to the loss of different 
subfunctions in each duplicate. The complementary pattern of subfunction loss ensures that 
both duplicates are required to perform the ancestral set of subfunctions and therefore both 
must be retained in the genome. There is an alternative, adaptive, way for the preservation 
of duplicate copies of a multifunctional gene. Duplicating such a gene provides a chance to 
eliminate the negative pleiotropic constraints, and allows the refinement of each 
subfunction by positive selection (Hughes, 1994; Piatigorsky and Wistow, 1991).
It should be noted that gene duplicates retained in the genome provide considerable 
molecular substrate for the later development of evolutionary novelty. Therefore the 
preservation of gene duplicates either through increased protein dosage or as a result of sub- 
functionalization is compatible with later acquisition of novel functions (He and Zhang, 
2005; Kondrashov et al., 2002).
Nevertheless, one member of a duplicate pair may directly diverge in function relative to 
the other. Therefore, when one paralog undergoes neofunctionalization, positive selection 
for this new function will result in a rate acceleration of the protein relative to its duplicated 
copy. An implicit assumption of the neofunctionalization model is that the second duplicate 
performs the ancestral gene’s function and continues to evolve at the same rate as its parent.
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This model shows that the preservation of gene duplicates by divergence in protein function 
can directly impact on rates of protein evolution.
However, the maintenance of duplicate genes by neofunctionalization or 
subfunctionalization can also proceed by divergence in gene expression profile. In this case, 
the immediate target of these preservational processes is the non-coding sequence 
responsible for gene expression regulation rather than the protein-coding sequence. The 
modularity of non-coding regulatory sequences makes them independently mutable and 
especially prone to the complementary degenerative mutations characteristic of 
subfunctionalization.
Expression divergence may also govern the sequence divergence of gene duplicates in 
multicellular eukaryotes. In mammals, population genetic considerations suggest that 
subfunctionalization is more likely to occur because of their small population sizes. As 
outlined above, the vulnerability of cis-regulatory sequences to degenerative mutations 
means that expression patterns are particularly susceptible to subfunctionalization. In fact, 
the partitioning of ancestral expression patterns can proceed both quantitatively (by a 
division of the ancestral expression level between duplicates so that their summed 
expression is required to fulfill ancestral function (Ferris and Whitt, 1979), spatially (by 
division of the constituent tissues of the ancestral expression domain among the duplicates 
(McClintock et al., 2002) or temporally (by division of expression at different 
developmental stages among the duplicates (Yan et al., 2005). In each case the divergence 
in expression is expected to result in an increase in evolutionary rate of the duplicates 
relative to the ancestral gene. In summary, it seems likely that asymmetry in expression 
between mammalian gene duplicates has the potential to explain some of their asymmetry 
in the rate of sequence divergence.
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1.10 Alkaline phosphatase gene family
One protein family in which the need for an ESE has influenced gene evolution is the 
Alkaline Phosphatase (ALP) family. ALPs are a family of homodimeric enzymes that 
catalyze the hydrolysis of monoesters of phosphoric acid with release of inorganic 
phosphate (McComb and Bowers, 1972), schematically shown in the following general 
reaction:
R-OP + H20  R-OH + Pi
Alkaline Phosphatases (ALPs) occur widely in nature and are found in many organisms 
from Escherichia coli to man. The catalytic site contains residues and cofactors that are 
preserved in different species and essential for enzymatic activity, i.e. the catalytic Ser and 
three metal ions (two Zn2+ and one Mg24) (Stec et al., 2000).
Although mammalian ALPs have different catalytic activity and affinity for the ligands this 
feature of the catalytic mechanism has been conserved during their evolution (Kim and 
Wyckoff, 1991). However, whereas the ALP in E. coli is situated in the periplasmic space, 
the enzymes, in mammals, are glycosylated ectoplasmic enzymes attached to the plasma 
membrane via a glycosylphosphatidylinositol (GPI) anchor.
In humans, ALPs are encoded by four distinct loci (Harris, 1990), traditionally named after 
the tissues in which they are expressed (Table 1.2). (1) The tissue non-specific ALP gene 
(ALPL) (Weiss et al., 1988), which encode the protein TNAP, has an ubiquitous 
expression, but with predominant presence in liver, bone and kidney, and in placenta during 
the first trimester of pregnancy (McComb et al., 1979). It has been shown to have an 
important role in mineralizing bone, where it is expressed on the plasma membrane of 
osteoblastic cells. (2) The intestinal ALP gene (ALPI) (Henthom et al., 1988), which 
encode the protein IAP, has been found in the brush border of the intestinal cells. (3) The 
placental ALP gene (ALPP) (Knoll et al., 1988), which encode the protein PLAP, has been 
found expressed in the syncytiotrophoblast from the first trimester of pregnancy to term. (4)
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The placental-like ALP gene (ALPPL2) (Millan and Manes, 1988), which encode the 
protein GCAP, has been found expressed in primordial germ cells and in small amount in 
testis and thymus.
The amino acid sequences of PLAP and GCAP are 98% similar. In the case of PLAP and 
IAP, there is 90% of similarity. The tissue-nonspecific (ALPL) is approx. 50% identical to 
the other three isozymes (Knoll et al., 1988; Le Du and Millan, 2002).
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Gene
name
Protein
name
Definition Chromosomal
location
Function
ALPL TNAP Tissue-
nonspecific
alkaline
phosphatase
chrl:p36.1-p34 Bone
mineralization
ALPP PLAP Placental
alkaline
phosphatase
chr2:q34-q37 Unknown
ALPPL2 GCAP Germ cell
alkaline
phosphatase
chr2:q34-q37 Unknown
ALPI IAP Intestinal
alkaline
phosphatase
chr2:q34-q37 Intestinal
absorption?
Table 1.2 Summary of gene nomenclature, protein names, chromosomal location and 
function, if known (Table taken from Millan, 2006).
Furthermore the human ALPs have been distinguished from each other by different 
methods: thermostability, inhibition, and immunologic studies.
Thermostability: PLAP and GCAP are highly thermostable. In contrast the other enzymes 
are inactivated under high temperature conditions. However, IAP is more stable than TNAP 
when treated at 56 °C (Harris, 1980).
Inhibition studies: ALPs have been shown to respond differently when treated with 
inhibitors through an uncompetitive mechanism. PLAP, GCAP and IAP were found to be 
more sensitive to L-phenylalanine than TNAP. Conversely, the TNAP is inhibited by L- 
homoarginine that affects in much less extent the other enzymes (Lin and Fishman, 1972).
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Instead L-leucine and an unrelated compound, Levamisole, are particularly strong inhibitor 
of GCAP and TNAP respectively.
Immunologic studies: TNAP is the only enzyme that does not cross-react with antisera 
raised in rabbits against placental ALP. Hence, IAP and GCAP are more closely related 
immunologically to PLAP than is TNAP (Lehmann, 1980).
In mammals only few compounds have been confirmed to be a natural substrate. Inorganic 
pyrophosphate (PPj) has been well documented that the hydrolysis to Pj by TNAP, thus 
providing Pi needed for bone mineralization (McComb et al., 1979). A natural substrate of 
TNAP is also pyridoxal-5’-phosphate (PLP) (a phosphorylated form of vitamin B6). ALPs 
appear also to be involved in the metabolism of nucleotides and sugars (Say et al., 1991). 
The gene structure of these 4 proteins also shares some similarity. The coding regions 
include a signal peptide (17-21 amino acids), which is cleaved off in the mature protein. 
The human tissue-specific genes, ALPP, ALPPL and ALPI, are clustered on human 
chromosome 2 (2q34-q37) and they are closely related to one another. Their structures are 
nearly identical, consisting of 11 exons at analogous positions and the similarity between all 
three genes suggests a divergent evolution. ALPL on the other hand is located on the short 
arm of chromosome 1 (lp36.12) with a length of 69 Kb, five times superior than each other 
three genes and has 12 exons compared with 11 in the tissue specific alkaline phosphatase 
genes (TSAP); the first exon is at the 5’ end in the non coding region and the second exon 
contains also the start codon for translation. The difference in the length is due to larger 
introns in ALPL gene. Notwithstanding these differences the coding regions are interrupted 
however in similar positions in all genes and are comparable also in length (Fig 1.8)
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Chr1: p36.1-p34 69,04 Kb
ALPL
1Kb
4,36 Kb
ALPP
1Kb
Figure 1.8. Diagram showing the genomic organization of ALPL and ALPP genes. In this 
graphic, exons are represented by boxes and introns by lines. Figure modified from (Harris, 
1990).
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2. AIM OF THE THESIS
It is well established that exonic sequences contain ESEs that overlap with coding capacity 
and that these may influence protein evolution. However, there has been a lack of 
experimental data that investigate the effect of how the need for ESE might influence the 
amino acid composition and protein activity of evolutionary correlated proteins.
For this reason, the aim of the PhD thesis was to investigate if the coexistence of exon 
splicing enhancer elements with amino acidic coding capacity might restrict the 
evolutionary selection of codon variants that could affect the protein function. Therefore, at 
least in a fraction of the exons that are present in the genome, suboptimal protein function 
might be tolerated to allow the persistence of sequences that are essential for exon inclusion 
(Pagani and Baralle, 2004; Pagani et al., 2005) (Fig. 1.9). The principal line of investigation 
taken in my PhD is to see if there is a combinatorial effect between exonic splicing 
enhancers, splice sites strength and protein activity. In order to do so, ideal candidate gene 
families in which evolution at the protein level may be hindered by the presence of cis- 
acting regulatory elements need to be identified (bioinformatic collaboration). In particular, 
we searched for paralogous gene families in which differences in the amino acid sequence 
are associated with the presence or absence of hypothetical ESE, and the presence of these 
ESE could in turn be associated to weaker splice site strengths.
50
/ x  Ancestral gene
m m m m m
T R
[ " I
' natural selection eliminates 
the mut and favours ancestor
Protein 
with no 
enzymatic 
activity ^
m
exon skipping 
\
\ \/  new mutation
r n  [ DUU AGU CGC I l ""i
F S R
/
LL2J><L affects an 
exonic splicin 
modulator
does not affect an 
exonic sr 
modulator
natural selection can favour 
new mutant over ancestor
Protein with 
f /  different
enzymatic 
activity
\
c A
exon inclusiont
Figure 2.1. The primary selective pressure on exons is for their inclusion in mRNA. The 
selection of a new amino acid that leads to a better enzyme can occur only if the codon 
substitution caused by a genetic mutation, does not affect an exonic regulatory element. In 
this model it is assumed that the threonine to serine change at the catalytic site will produce 
a more active enzyme that has a selective advantage. However the C to G substitution has 
to be compatible with the splicing machinery that identifies the exon. If the inclusion is 
guaranteed, then the amino acid change is favoured. If not, exon skipping will result in an 
inactive enzyme and the ancestral threonine that produces a suboptimal protein will be kept 
to ensure the exon inclusion step. Figure modified from Pagani and Baralle (2004).
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3. RESULTS
3.1 ESE Analyzer Web Server (EAWS) computational analysis
The nucleotides present in the exonic sequence not only code for the amino acids of 
the protein but can also play a role in splicing, coding for splicing cis-acting elements such 
as ESE. This has led to the hypothesis that the splicing regulatory elements may restrict the 
choice of amino acids in these areas and, therefore, possibly also influence protein activity 
(Pagani and Baralle, 2004; Pagani et al., 2005).
In order to identify possible candidate genes in which the evolution of exon sequences 
might be constrained by the presence of ESE, I looked at closely related human paralogous 
genes in which the protein function and exonic organization were maintained during 
evolution. The search criteria was to find a protein family which had a measurable 
enzymatic activity that would allow subsequent analysis of the constraint that may occur 
between optimal splicing and optimal protein functions with greater ease. This hypothetical 
family of paralogous proteins would have members with different amino acids within or 
close to the functional domain and these differences in residue composition would 
correspond to creation or disruption of an ESE. In order to aid the screen, as ESE are often 
present in exons with “weak” 3 or 5’ ss (see section 1.5.1), I also searched for scenarios in 
which weak/strong splice sites are associated with the presence/absence of ESE within the 
same paralogous family. Therefore, ideal candidates were paralogous genes within which a 
member would have ESE constraining variation that would have effects on functional 
characteristics of the protein and that the presence or absence of these ESE sequences 
correlated respectively to weak and strong splice sites.
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In order to perform this search at a level of a wide screen it was necessary to integrate 
information from several bioinformatic tools, a complex and time consuming task with 
visually hard data sets to follow. To overcome these problems, a bioinformatic platform 
was created to identify candidate paralogous genes: ESE Analyzer Web Server (EAWS). 
This program was developed in collaboration with Dr. Vlahovicek (University of Zagreb, 
Croatia) and provides information related to splicing regulatory sequences in a visually 
clear manner. Since as mentioned above, one of the difficulties in the screen was the 
visualization of the data sets, an important characteristic of EAWS is that it is built on user- 
friendly interface that is a crucial point in order to facilitate access to information for the 
user. Indeed, the user can obtain a list of candidate genes by either entering via the Interpro 
domain identification key (e.g. IPR001952), submitting the sequence in FASTA format, 
inserting Transcript/Exon ID or using a keyword (e.g.protease, phosphatase) (Fig. 3.1).
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ESE Analyzer Web Server (EAWS)
Backarcund Methods C 'cd its HelD ©I
Please en ter: ©
InterPro ID: 3
or:
Paste your s e t  of seq u ences in FASTA fo rm at or en te r Ensembl T ranscrip t/ Exons IDs:l ©
or upload a file: | Browse... j
Align sequences
Submit | Reset j
K eyw ord(s): Ji....... .. ©
Submit 1 Reset
Figure 3.1. Start page of ESE Analyzer Web Server (EAWS). 1- Link to Introduction 
(background, methods, etc.,); 2- textbox for Interpro ID input; 3- textbox for user submitted 
sequence and/or Ensemble exon and transcript IDs; 4- choice to align submitted sequences; 
5- choice to search domains by keyword.
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The greatest innovation of this platform is that EAWS is able to integrate information from 
different sources available to date regarding splicing from the existing web servers: Gene 
Splicer that predicts the 3’ and 5’ ss strength (Pertea et al., 2001); FAS-ESS that predicts 
exonic splicing silencer (Wang et al., 2004); ESE RESCUE (Fairbrother et al., 2002); 
ESEfinder (Cartegni et al, 2003). Regarding the latter, the sensitivity threshold can be 
adjusted. Furthermore, EAWS contains all Interpro (Hunter et al., 2009) protein domains 
that have annotated transcripts in Ensembl (Flicek et al., 2010). All genes that have 
conserved protein domains were fetched from Ensembl and transcripts analyzed for the 
presence of splicing regulatory sequences. It also allows, at the same time, to align 
transcripts and protein sequences of similar functional domains (Fig. 3.2). This multiple 
sequences alignment is done through the use of MUSCLE program. Protein sequence of 
only one domain instance per gene was selected for an alignment, from a reference 
transcript of that gene. If there are multiple domain repeats within a gene, only the first 
repeat was selected. In this way, each gene is represented with a part of its sequences that 
codes for distinct protein domain. Therefore, the alignment of functional domains from 
human paralogs would provide ideal candidates in which evolution at the protein level may 
be hindered by the presence of cis-acting regulatory elements.
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ESE Analyzer Web Server (EAWS)
Sequences submitted.
Return j
Exonic Splicing Regulators
ESEfinder
Select one or more matrices:
Matrices RelativeThresholds
Absolute
Thresholds
F  SF2/ASF 90 % 4.873
F  SC35 90 % 4.822
F  SRp40 90 % 4.66
F  SRp55 90 % 4.578
Change all
I _______ _________ ___  -
%
RESCUE ESE Exonic splicing silencers (ESS)
Find ESE predictions Find ESS predictions
Output
Display non-aligned sequences in an alignment format 
Display j 90 bases in a row
Send me results to email:
Figure 3.2. Page for selecting options in EAWS. 1- different bioinformatics servers for the 
analysis of exonic splicing regulators, 2- output options as well as thresholds.
An example of an analysis is shown in figure 3.3. Entering via the Interpro domain 
identification key IPR023412 (Ribonuclease A domain), EAWS fetch in Ensembl all the 
transcripts that have RNase A domain. The selected transcripts are analyzed for ESE Finder, 
ESE-RESCUE and ESS motifs and aligned.
The first line, in green, represents the consensus sequence with above 50% of amino acid 
conservation. The amino acids and corresponding nucleotide triplets are aligned below.
The numbers at the beginning of each block line indicate the amino acid/nucleotide 
positions in the corresponding proteins/transcripts. Nucleotides in red are predicted
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ESEfinder motifs, underlined are predicted ESE-RESCUE hexanucleotides. In the 
transcripts, exon borders (the last nucleotide of the preceding exon and the first nucleotide 
of the next exon) are highlighted in different colours depending of the splice site strength 
(darker is stronger donor/acceptor); and in protein sequence highlighted in orange is the 
amino acid principally involved in the active site.
Output example: Ribonuclease A domain
PR 023412 RtBCNUCLEASE A. DOMAIN
R e p o r t  F ile s : ..... ,
IPR023412 alt RNDER ESE out 
IPR323412 all RESCUE ESE out 
IPR02341? all ESS out
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Figure 3.3. A typical output page of EAWS for Ribonuclease A domain. An example on 
how to read the EAWS output. 1 -  consensus sequence above 50% of amino acid 
conservation; 2 -  range of residues in the line for each sequence (The numbers at the 
beginning of each block line indicate the amino acid/nucleotide positions in the 
corresponding proteins/transcripts); 3 -  predicted ESEfinder motifs; 4 -  predicted 
RESCUE-ESE (underlined); 5 -  exon borders (the last nucleotide of the preceding exon and 
the first nucleotide of the next exon) highlighted in different colors depending of the splice 
site strength (darker is stronger donor/acceptor); 6 -  Protein ID; 7 - the amino acid mainly 
involved in the active site; 8- Color coding of the output of the splice site strength.
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3.1.1 Candidate protein families selected via EAWS
Using EAWS platform several possible candidate genes were found to comply with 
our search criteria. Figure 3.4 shows three examples that I regarded as the most promising 
candidates: (A) Vacuolar-type proton pump (H+-ATPase) G subunit (ATP6V1G), (B) 
Protein Phosphatase type 2A B' subunit (PPP2AR) and (C) Alkaline Phosphatase (ALP). 
Briefly, in each case amino acid differences were observed in family members 
corresponding to nucleotide changes that in turn created or disrupted ESE and the presence 
of these ESE could be associated with weak 5’ or 3’ ss.
Specifically, the multi-subunit H*-ATP ase comprises two functional domains, Vi and Vo. 
The peripheral Vi domain binds and hydrolyzes ATP, providing the energy for 
H+ translocation across the integral membrane Vo domain and each domain contain several 
subunits. In particular, ATP6V1G is referred to H+-ATPase G subunits localized in the 
catalytic domain Vi (Beyenbach and Wieczorek, 2006). In this case, in the exon three of the 
transcripts ATP6V1G3 (line #3) and ATP6V1G1 (line #5), associated with a weak 3’ss, I 
observed a correlated increase in the number of predicted ESEs. In ATP6V1G1 there was 
also an amino acid variation in the area of a predicted ESE encoding for an Arg with 
respect to the other members where the Gin is highly conserved or as in the case of 
ATP6V1G3 a predicted ESE encoded for an He where in all the other members a Val 
residue was present (Fig. 3.4A).
The core enzyme of the Protein Phosphatase type 2A (PP2A) comprises a dimer (PP2AD), 
consisting of a catalytic subunit (PP2AC) and a regulatory subunit termed A subunit. A 
third regulatory B subunit can be associated with this core structure. At present, four 
different families of B subunits have been identified, termed the B, B', B " and B '"  
families. In particular PPP2AR is referred to the PP2A regulatory B ' subunit (Lechward et 
al., 2001). In this case, the EAWS analysis showed the absence of a predicted ESEfinder 
motif in the 3’ end of the PPP2R5A exon two (line #2), resulting in lie amino acid variation 
where Leu is instead present in all the other members (area 1) and the increase in acceptor
strength in the exon five of the transcript PPP2R5B (line #3) is compensated by the 
decrease of an ESE (area 2) that was not associated with any amino acid variation (Fig. 
3.4B).
However, the most promising candidate protein family were those of the human Alkaline 
Phosphatase paralogous genes (ALPs) (Fig. 3.4C).
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Figure 3.4. Partial alignment of candidate gene families. (A) Partial alignment of Vacuolar 
(H+)ATPase G subunit (ATP6V1G) (Interpro domain IPR005124) localized in the catalytic 
domain Vi. In this case, in the exon three of the transcripts ATP6V1G3 (line #3) and 
ATP6V1G1 (line #5), associated with a weak 3’ss, there is an increase in the number of 
predicted ESEs. In ATP6V1G1 there was also an amino acid variation in the area of a 
predicted ESE encoding for an Arg and in ATP6V1G3 a predicted ESE encoded for an lie 
with respect to the other members of the family where the these amino acids are highly 
conserved. (B) Partial alignment of Protein Phosphatase 2 A, regulatory B' subunit (PP2AR) 
(Interpro domain IPR002554). In this case, the EAWS analysis showed the absence of a
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predicted ESEfinder motif in the 3’ end of the PPP2R5A exon two (line #2), resulting in lie 
amino acid variation where Leu is instead present in all the other members (area 1) and the 
increase in acceptor strength in the exon five of the transcript PPP2R5B (line #3) is 
compensated by the decrease of an ESE (area 2) that was not associated with any amino 
acid variation. (C) Partial alignment of Alkaline Phosphatase gene family (Interpro domain 
IPR001952) in which compensatory changes in acceptor strength follow changes in ESE 
and amino acid variations (area 3) close to the active Serine, in orange (see below).
In humans, ALPs are encoded by four distinct loci, traditionally named after the tissues 
where they are predominantly expressed (Table 1.2). The placental ALP (ALPP), the germ 
cell ALP (ALPPL) and the intestinal ALP (ALPI) isozymes are tissue-specific and 90-98% 
homologous, while the tissue-nonspecific (ALPL) is approx. 50% identical to the other 
three isozymes (see introduction). From the analysis the ALPs human transcripts, using the 
ESE Analyzer Web Server, the exon 4 of the tissue- specific genes and the exon 5 of the 
non-tissue specific isoform, that enclose the active site of the enzymes, match at the amino 
acid level with a high degree of homology and fulfilled many of my search criteria (Fig. 
3.5). Indeed this analysis showed: a weak 3’ ss of exon 4 in the tissue specific ALP genes 
and a strong 3’ ss in exon 5 of ALPL gene. The investigation of the cis-acting splicing 
regulatory elements through ESE RESCUE and ESE Finder, highlighted several elements. 
As the ESE RESCUE motifs identified were not associated with changes in amino acid 
composition correlated to the ALP’s with the “weak” 3’ splice site or where universally 
present in all the ALPs I decided to concentrate the initial studies on the splicing cis acting 
regulatory elements identified by ESE finder. In this case ESEfinder identified in 
correspondence to the ALPP transcript exon 4, that has a weak 3’ss as calculated by Gene 
Splicer (see Tab. 1.1), two hypothetical ESEfinder motifs, which are absent in the 
corresponding sequences of the ALPL gene, in particular exon 5, that carries a strong 3’ss 
(Fig. 3.5, areas 1 and 2). The nucleotide changes in the corresponding region of ALPL exon
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5 that resulted in the absence of these hypothetical ESE also resulted in amino acid 
variations in this region that, in the other members of the family is well conserved. A third 
putative ESEfinder motif is also present, partially overlapping in all 4 ALPs. There was also 
an amino acid variation in the area of predicted ESEs of ALPL exon 5 with respect to the 
other ALPs where the Ala is highly conserved. However, in this scenario there is no 
connection between presence or absence of ESE with 3’ ss strength (Fig. 3.5, area 3). 
Intriguingly, the amino acids of interest that differ between PLAP and TNAP, in the predicted 
ESEfinder motifs, may play a role in the catalytic protein function, for the proximity to the 
active Serine highlighted in orange.
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Figure 3.5. Output of EAWS showing the comparative analysis of the exon encoding for 
the active site of human Alkaline Phosphatase (ALP) family. (A) Alignment of exonic 
sequences and corresponding amino acidic sequences of human placental (ALPP), germ
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cell (ALPPL2), intestinal (ALPI) and tissue non-specific (ALPL). The numbers at the 
beginning of each block line indicate the amino acid/nucleotide positions in the 
corresponding proteins/transcripts. Nucleotides in red are predicted ESEfinder motifs and 
sequences underlined are ESE-RESCUE motifs. The ESE areas and its homologous 
sequence in ALPL are boxed (1-3). The exon borders are highlighted in different colors 
depending of the splice site strength (darker is stronger donor/acceptor); (B) Color coding 
of the output of the splice site strength.
3.2 Analysis of ESE bioinformatics predictions
Since the current understanding of the properties of human ALPs comes from 
studies using ALPP and ALPL as paradigms, (Le Du and Millan, 2002) I decided to use 
these in the following study. In order to confirm the bioinformatic predictions I initially set 
up a minigene assay to test if this was a viable methodology with which to map the 
presence or lack of ESE in ALPP and ALPL respectively (see material and methods for a 
detailed description). As it has often being shown that the adjacent flanking sequences are 
also important for the definition of the exon I decided to create three exon-two intron 
minigene, thus creating (Buratti et al., 2006) as natural as possible environment for the 
specific exon under study. I therefore generated the minigenes ALPP and ALPL that 
spanned exons 3 to 5 and exons 4 to 6 respectively, with the exon under study always being 
the central one (Fig. 3.6A).
Transfection in HeLa cells followed by RT-PCR analysis showed that in the case of ALPL 
minigene a unique PCR product of 467 bp is observed. This was identified, through 
sequencing, as normal inclusion of exon 5 in the mature transcript (Fig. 3.6B, Lane 1). The 
RT-PCR of the ALPP minigene carrying the exon 4 with its flanking intronic and exonic 
sequence, showed a major amplicon of 464 bp, corresponding to the normal inclusion of the 
exon 4 and a very minor amplicon of higher molecular weight (Fig. 3.6B, Lane 2).
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Sequencing of the cDNA fragment showed that the minor fragment was composed of a 
complete inclusion of the intron 4.
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Figure 3.6. Wild type splicing patterns of ALPP and ALPL minigenes. (A) Schematic 
representation of the wild type hybrid minigenes used in transfection experiments. The 
exons of interest are shown in green. (B) The amplified RT-PCR products stained with 
ethidium bromide after transfection in HeLa cells. RT-PCR analysis of ALPL minigene 
showed a unique PCR product of 467 bp corresponding to normal inclusion of exon 5 in the 
mature transcript (Lane 1). The RT-PCR of the ALPP minigene carrying the exon 4 with its 
flanking intronic and exonic sequence, showed a major amplicon of 464 bp, corresponding 
to the normal inclusion of the exon 4 and a very minor amplicon of higher molecular weight 
produced by the retention of the intron 4. A faint band at about 700 bp is most probably due 
to contamination of plasmid DNA (Lane 2).
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Although minigenes represent a useful tool with which to analyze splicing mechanisms, 
they can result in artificial outcomes due to the reduced amount of gene sequence utilized. 
Regarding this issue, previous studies have clearly shown that apparent discrepancies in 
comparisons between minigenes and endogenous situations can sometimes be due to long 
distance interactions and the balance of these controls the correct splicing outcome. In 
particular, it has been shown that in the NF1 (neurofibromatosis 1) gene the genomic 
context plays a very important role in explaining apparent discrepancies between minigenes 
and endogenous situations (Baralle et al., 2006). Moreover, using hybrid minigene 
experiments, it has been shown that changes in promoter, in this case using CMV promoter 
of the pcDNA3 minigene instead of the endogenous, could strongly affect splice site 
selection (Komblihtt, 2005; Pagani et al., 2003b).
In order to establish whether the retention of intron 4 in ALPP minigene occurs also 
endogenously in human placental tissue or if it represented an artefact of the minigene 
system, I analyzed the endogenous splicing pattern of the exon 4 from placental tissue. As 
can be seen in figure 3.7 the RT-PCR did not reveal any retention of the intron 4 in vivo, 
but a unique PCR product of 464 bp, corresponding to the normal processing. Based on the 
assumption that this intron retention was an artefact of the minigene system, the 
corresponding splicing product was not considered in further studies.
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Figure 3.7. Wild type splicing patterns of endogenous ALPP exon 4 processing. (A) 
Schematic representation of the amplified portion from the endogenous transcript. (B) The 
amplified RT-PCR products from human placental RNA stained with ethidium bromide. 
The RT-PCR did not reveal the retention of the intron 4 in vivo, but a unique PCR product 
of 464 bp, corresponding to the normal processing.
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3.2.1 Analysis of ALPP exon 4 processing after mutations in two regions where the 
presence of ESE is predicted and associated with weak 3’ splice sites
From EAWS bioinformatics analysis of ALPP and ALPL transcripts, the ALPP 
exon 4 showed predicted ESE motifs that were absent in corresponding sequences of ALPL 
exon 5, these differences were also associated with amino acidic variations close to the 
active site of the enzymes (Fig. 3.5, areas 1 and 2). I started the investigation verifying the 
predictions of the bioinformatics analysis. A schematic representation of the central part of 
the wild type (WT) minigenes, the exon 4 and its flanking intronic region in the case of 
ALPP minigene and exon 5 and its surrounding intronic sequences for ALPL construct is 
shown in figure 3.8A. The analysis of ALPP exon 4 for putative ESE with ESEfinder 
highlighted two regions containing a total of 3 putative ESE associated with a weak 3’ ss as 
well as with amino acids changes that were not detected in the analogous region of ALPL 
(1st seq and 2nd seq) exon 5 that carried a strong 3’ splice site. The 2nd ESE region contained 
two putative enhancers, however, given their proximity this area was initially analyzed as 
one. To test the bioinformatic predictions I decided to generate minigenes where the regions 
corresponding to the ALPP 1st and 2nd putative ESE were exchanged individually with the 
corresponding ALPL sequences (1st seq and 2nd seq) (Fig. 3.8A, MUT1-2), which were 
predicted not to have ESEs. Minigenes were then transfected in HeLa cells. RNA was 
extracted and than subjected to RT-PCR analysis. The rationale behind this experiment was 
that if it was indeed the case that the ESEs in ALPP were needed for correct splicing of this 
exon, and that if this was not the case in the corresponding region of ALPL, an aberrant 
splicing of ALPP exon 4 would be observed.
As can be seen in Figure 3.8B the replacement of the 1st and 2nd predicted ESEs with the 
corresponding area in ALPL resulted in a decrease in exon definition with a partial exon 4 
skipping in both cases. These results confirmed the bioinformatics prediction, that these two 
regions of the exon 4 contain enhancer elements responsible for promoting the exon
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inclusion in HeLa cells and it is for such reason that I will refer them to as the 1st and 2nd 
ESE element regions.
To see if the ESEs were acting in union I decided to create a minigene in which I 
exchanged the 1st and 2nd ESE element regions for the corresponding region in ALPL (1st 
seq and 2nd seq) simultaneously, creating the minigene MUT3 (Fig. 3.8A). Transfection into 
HeLa cells, followed by RT-RCR analysis and agarose gel electrophoresis, showed that 
exon 4 skipping increases drastically when both ESE element regions were substituted for 
the corresponding region of ALPL, hence demonstrating a cumulative effect of ESE 
sequences present in these two areas (Fig. 3.8C).
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Figure 3.8. Analysis of ALPP exon 4 splicing after swapping the regions 1st and 2nd ESE 
with that of ALPL. (A) A schematic representation of the central part of the wt ALPP and 
ALPL constructs, the exon of interest is shown in green and its flanking intronic region as 
black line and the investigated wt sequences are represented above the exon (1st and 2nd seq 
in ALPL exon 5; 1st and 2nd ESE in ALPP exon 4). The sequences reported nearby the 
mutants (MUT1-3) show the substitutions performed on the minigenes. (B) The amplified 
RT-PCR products stained with ethidium bromide after transfection in HeLa cells. The
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inversion of the 1st and 2nd predicted ESEs with the corresponding area in ALPL resulted in 
a decrease in exon definition with a partial exon 4 skipping. (C) Transfection into HeLa 
cells, followed by RT-RCR analysis and agarose gel electrophoresis, showed that exon 4 
skipping increases when both ESE sequences were substituted for the corresponding region 
of ALPL. On the right hand site of the gels a schematic representation of the splicing 
product obtained can be observed. The percentage of skipping and standard deviation (SD) 
are indicated below each lane and represent the mean of three experiments.
Afterward, I decided to investigate also if 1st and 2nd seq element in ALPL could 
differentially affect the efficiency of the exon 5 inclusion when exchanged for the 
corresponding sequence of ALPP. Therefore, I generated two minigines in which 1st and 2nd 
seq element were separately replaced with the 1st and 2nd ESE in the ALPL minigene and a 
minigene in which I exchanged the 1st and 2nd seq element regions for the corresponding 
region in ALPP (1st and 2nd ESE) simultaneously (Fig. 3.9A). The substitution of the 1st and 
2nd seq, in the exon 5, with the 1st and 2nd ESE elements, as expected, did not compromise 
the correct inclusion of the exon 5 in the mRNA (Fig. 3.9B).
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Figure 3.9. Analysis of ALPL exon 5 splicing after swapping the regions 1st and 2nd seq 
with that of ALPP. (A) A schematic representation of the central part of the wt ALPP and 
ALPL constructs, the exon of interest is shown in green and its flanking intronic region as 
black line and the investigated wt sequences are represented above the exon (1st and 2nd seq 
in ALPL exon 5; 1st and 2nd ESE in ALPP exon 4). The sequences reported nearby the 
mutants (MUT4-6) show the substitutions performed on the minigenes. The constructs are 
analyzed with pcDNA3 minigene system in HeLa cells. (B) RT-PCR performed from 
RNAs isolated from HeLa cells previously transfected with the mutated minigene. In
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MUT4-6 the inversion of the 1st and 2nd seq with the corresponding area in ALPP did not 
compromise the correct inclusion of the exon 5 in the mRNA (n=3). On the right hand site 
of the gels a schematic representation of the splicing product obtained can be observed.
3.2.2 Experimental validation of ESE present in both ALPP and ALPL exon 4 and 5 
respectively
As shown in figures 3.5 and 3.10A the bioinformatics analysis also identified a 
putative ESE sequence through ESEfinder in ALPP exon 4 in addition to those present in 
the 1st and 2nd ESE region analyzed above. Although the region covered by the ESE was 
also associated with an amino acid difference between the tissue specific and non tissue 
specific ALP in the latter, ALPL, the putative ESE was found to partially overlap with a 
predicted ESEfinder motif but in this case the predicted enhancer makes no distinction 
between presence or absence of ESE with 3’ ss strength. Even though the search criteria, in 
this case, were not completely fulfilled I investigated the functional role of these putative 
ESE in the inclusion of ALPP exon 4, disrupting this putative ESE motif and analyzing 
whether this mutation affects splicing. In this case simple convers ion of the sequence for 
that of ALPL would not provide the answer we were looking for as an ESE also exists in 
this region. Using ESEfinder prediction I found that a single base deletion could cause the 
loss of ESEfinder motif in both ALPL and ALPP. Indeed, it showed that after G nucleotide 
deletion the sequences are no more recognized as enhancer (Fig. 3.1 OB).
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Figure 3.10. Putative ESE present in both ALPP and ALPL exon 4 and 5 respectively. (A) 
Alignment of exonic sequences and corresponding amino acid sequences of human 
placental (ALPP) and tissue non-specific (ALPL). Overlapping predicted ESE in paralogous 
genes are boxed. Nucleotides in red are predicted ESEfinder motifs. (B) Results from 
analysis with ESEfinder web-resource (http://rulai.cshl.edu/tools/ESE/). The y-axis is the 
numerical-scale for the ESE score; x-axis shows the four different sequences analyzed. The 
ESEfinder prediction shows that after nucleotide deletion (AG; above underlined) the 
sequences are no more recognized as enhancer sequence.
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Therefore, I created a series of constructs with deletion of the overlapping G 
nucleotide (TGCAGC, underlined nucleotide) in the ALPP minigene (Fig. 13.11 A, MUT7- 
10). In particular, MUT7 carried only AG mutation in ALPP wt minigene context and was 
made to see whether disrupting this putative enhancer could have an effect in the exon 4 
pre-mRNA splicing. The MUT8, 9 and 10 were made on the base of the previous mutated 
minigenes MUT1, 2 and 3, respectively, with the addition of G nucleotide deletion in the 3rd 
putative ESE (Fig. 3.11 A). After RT-PCR analysis, I observed that the MUT7, 8, 9, and 10 
had no consequences on the inclusion of ALPP exon 4 in the mRNA (Fig. 3.1 IB).
As this deletion, did not have any effect on the inclusion of exon 4 , 1 therefore decided to 
not consider this putative ESE sequence as important in the exon 4 inclusion and was not 
further investigated.
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Figure 3.11. Analysis of ALPP exon 4 splicing after AG mutation in the 3rd putative ESE. 
(A) A schematic representation of the central part of the wt ALPP and ALPL constructs, the 
exon of interest is shown in green and its flanking intronic region as black line and the
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investigated wt sequences are represented above the exon (1st and 2nd seq in ALPL exon 5; 
1st and 2nd ESE in ALPP exon 4). The sequences reported nearby the mutants (MUT7-10) 
show the substitutions performed on the minigenes. In particular, the nucleotide deletion in 
the 3rd putative ESE sequence is underscored in the sequences overhead. (B) The splicing 
pattern observed upon transfection of these constructs in HeLa cells. The AG mutation did 
not have any effect on the inclusion of exon 4. On the right hand site of the gel a schematic 
representation of the splicing product obtained can be observed. The percentage of skipping 
and standard deviation (SD) are indicated below each lane and represent the mean of three 
experiments.
3.2.3 Fine mapping of the ESE
Having established the presence of the ESEs motifs in the ALPP exon 4 and their 
absence in the corresponding sequence of ALPL I decided to further define these regions, to 
know which amino acid changes were directly linked to ESE activity as the first mapping 
was performed in a broad fashion as a first approach and contained 5 amino acid 
differences (Fig. 3.5). The 1st and 2nd ESE regions were therefore further analyzed by 
exchanging each nucleotide triplet with the corresponding nucleotides encoding for the 
amino acidic observed in ALPL. Initially, given that the 1st ESE region presents two 
different amino acidic changes in ALPL, Gly93 and Ala94, when compared to the 
corresponding region in ALPL (1st seq) I created a series of minigenes in which I mutated 
each triplet encoding for glycine 93 or alanine 94 into their counterparts in ALPL, alanine 
and glycine codons (underlined in figure 3.12A), as well as a third minigene in which both 
triplets were mutated (Fig. 3.12A, MUT11-13). Transfection and RT-PCR of these 
constructs showed in all cases a partial exon 4 skipping (Fig. 3.12B), indicating that both 
triplets in the 1st ESE region are necessary for the correct processing of the exon 4. 
Considering the fact that these triplets are adjacent it is very likely that they are part of the 
same ESE element.
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Figure 3.12. Analysis of ALPP exon 4 splicing after mutations in the 1st ESE codons that 
lead to amino acid difference in ALPL. (A) A schematic representation of the central part of 
the wt ALPP and ALPL constructs, the exon of interest is shown in green and its flanking 
intronic region as black line and the investigated wt sequences are represented above the 
exon (1st and 2nd seq in ALPL exon 5; 1st and 2nd ESE in ALPP exon 4). The sequences 
reported nearby the mutants (MUT11-13) show the substitutions performed on the
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minigenes. In particular, the nucleotide changes in the 1st ESE sequence are underlined in 
the sequences overhead. (B) The splicing pattern observed upon transfection of these 
constructs in HeLa cells. MUT11-13 contribute to alter the splicing pattern of the exon 4. 
On the right hand site of the gel a schematic representation of the splicing product obtained 
can be observed. The percentage of skipping and standard deviation (SD) are indicated 
below each lane and represent the mean of three experiments.
The ALPP 2nd ESE region is, instead, associated with three amino acidic changes in the 
triplets encoding for A snll9, Glnl20 and Argl25 when compared to the equivalent region 
in ALPL (2nd seq). Therefore, as I did for the 1st ESE region, I investigated the effect of the 
nucleotide triplet differences also for the 2nd ESE region. I converted the single codons 
encoding for asparagine 119, glutamine 120 and arginine 125, into serine, arginine and 
glutamine (underlined in figure 3.13A), respectively, by site directed mutagenesis, giving 
rise to the new minigene constructs (Fig. 3.13A, MUT14-16). Interestingly, transfection 
followed by RT-PCR analysis showed that, among these three constructs, only the triplet 
corresponding to the arginine 125 affects the splicing in this region (Fig. 3.13B). Thus only 
this triplet was considered to be associated with ESE function.
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Figure 3.13. Analysis of ALPP exon 4 splicing after mutations in the 2nd ESE codons that 
lead to amino acid difference in ALPL. (A) A schematic representation of the central part of 
the wt ALPP and ALPL constructs, the exon of interest is shown in green and its flanking 
intronic region as black line and the investigated wt sequences are represented above the 
exon (1st and 2nd seq in ALPL exon 5; 1st and 2nd ESE in ALPP exon 4). The sequences 
reported nearby the mutants (MUT14-16) show the substitutions performed on the 
minigenes. In particular, the nucleotide changes in the 2nd ESE sequence are underlined in 
the sequences overhead. (B) The splicing pattern observed upon transfection of these 
constructs in HeLa cells. RNA splicing variants corresponding to ALPP exon 4 inclusion
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and exclusion are shown. Only MUT16 affects the splicing in this region. On the right hand 
site of the gel a schematic representation of the splicing product obtained can be observed. 
The percentage of skipping and standard deviation (SD) are indicated below each lane and 
represent the mean of three experiments.
To address the question of whether the synergic effect of the two ESE elements still occurs 
as was observed with ESE region 1 and 2, see figure 3.8 MUT3,1 examined the effect that 
these finer mapped enhancer sequences have in combination on the splicing efficiency of 
the ALPP exon 4. The minigene used to do this had the two triplets encoding for Gly93, 
Ala94 and the triplet encoding for the Argl25 exchanged for the corresponding triplets in 
ALPL (Fig. 3.14A, MUT17). As shown in Fig. 3.14B, the mRNA processing showed that 
the MUT17 now behaves as the MUT3 minigene, displaying an exon skipping of about 
80%. Also in this case the cooperative effect of enhancer sites is maintained for the specific 
recognition of the exon, leading to a correct pre-mRNA splicing.
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Figure 3.14. Analysis of ALPP exon 4 splicing after swapping of redefined regions 1st and 
2nd ESE with that of ALPL associated to amino acidic differences. (A) A schematic 
representation of the central part of the wt ALPP and ALPL constructs, the exon of interest 
is shown in green and its flanking intronic region as black line and the investigated wt 
sequences are represented above the exon (1st and 2nd seq in ALPL exon 5; 1st and 2nd ESE 
in ALPP exon 4). The sequences reported nearby the mutant (MUT17) show the 
substitution performed on the minigene. The nucleotide changes in the 1st and 2nd ESE
8 2
sequence are underlined in the sequences overhead. (B) RT-PCR products after the 
transient transfection of the minigenes constructs. RNA splicing variants corresponding to 
ALPP exon 4 inclusion and exclusion are shown. MUT17 behaves as the MUT3 minigene, 
displaying an exon skipping of about 80%. On the right hand site of the gel a schematic 
representation of the splicing product obtained can be observed. The percentage of skipping 
and standard deviation (SD) are indicated below each lane and represent the mean of three 
experiments.
3.2.4 The ESEs in ALPP are necessary due to a non consensus 3’ ss
It has been assumed that one function of ESEs is the recruitment of spliceosomal 
components to a weak splice site of an exon (Lam and Hertel, 2002). Indeed improving the 
strength of the splice site has already been demonstrated to counteract the enhancer 
requirements (Tian and Maniatis, 1994).
As previously mentioned the EAWS analysis included the evaluation of the splice sites 
strength. The 5’ss of the ALPP exon 4 and ALPL exon 5 was in both cases considered 
strong. On the other hand, the 3’ss strength of the ALPP exon 4 was suboptimal with the 
ALPL 3’ ss being much stronger. This observation suggested that the weakness of the 3’ss 
strength in ALPP might represent the cause of the need of additional splicing regulatory 
elements to allow an efficient exon processing. To test this hypothesis and to investigate the 
influence of a weak 3’ ss strength on ALPP exon 4 splicing, I exchanged the weak 3’ss of 
ALPP with the stronger one of ALPL, creating the minigene MUT18 (Fig. 3.15A). To see if 
the substitution would have any effect on the inclusion of exon 4 the minigene was 
analyzed and after transfection and RT-PCR analysis (Fig. 3.15B), I observed that it 
functioned in an analogous way as to the ALPP wt minigene (Fig. 3.6B, Lane 2).
Using this construct (ALPP with the the stronger splice site of ALPL) as a backbone, I then 
created a series of minigenes, initially with the exchanged ESE region 1 and 2 (Fig. 15 A, 
MUT18-21), and subsequently in the context of finely mapped ESEs (Fig.3.16A, MUT22-
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24).
Transient transfection experiments in HeLa cells and subsequent RT-PCR analysis showed 
that the improvement of the 3’ splice site strength eliminates the need for ESE. Indeed, 
inclusion of ALPP exon 4 occurs, where before were observed different degrees of exon 4 
skipping, as shown comparing ALPP minigenes with endogenous splice site (weak), (Fig. 
8, 12, 13 and 14) and ALPP carrying the stronger splice site (Fig.l5B and 16B).
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Figure 3.15. Analysis of ALPP exon 4 splicing after swapping of weak 3’ss with that 
strong of ALPL exon 5 in minigenes that lack of ESE motifs. (A) A schematic 
representation of the central part of the wt ALPP and ALPL constructs, the exon of interest 
is shown in green and its flanking intronic region as black line and the investigated wt 
sequences are represented above the exon (1st and 2nd seq in ALPL exon 5; 1st and 2nd ESE 
in ALPP exon 4). The sequences reported nearby the mutants (MUT1-3; MUT18-21) show 
the substitutions performed on the minigenes. The exact exchanged sequences of both 
ALPP 3’ss (pink) and ALPL 3’ss (blue) are reported in full. The constructs are analyzed 
with pcDNA3 minigene system in HeLa cells. (B) RT-PCR performed from RNAs isolated 
from HeLa cells previously transfected with the mutated minigene. MUT19-21 the increase 
of the 3’ss strength resulted in the recovery of the exon. On the right hand site of the gel a 
schematic representation of the splicing product obtained can be observed. The percentage 
of skipping and standard deviation (SD) are indicated below each lane and represent the 
mean of three experiments.
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Figure 3.16. Analysis of ALPP exon 4 splicing after swapping of weak 3’ss with the
stronger one of ALPL exon 5 in minigenes that lack of refined ESE motifs. (A) A
schematic representation of the central part of the wt ALPP and ALPL constructs, the exon 
of interest is shown in green and its flanking intronic region as black line and the 
investigated wt sequences are represented above the exon (1st and 2nd seq in ALPL exon 5; 
1st and 2nd ESE in ALPP exon 4). The sequences reported nearby the mutants (MUT22-24) 
show the substitutions performed on the minigenes. The exact exchanged sequences of both 
ALPP 3’ss (pink) and ALPL 3’ss (blue) are reported in full. The nucleotide changes in the 
1st and 2nd ESE sequence are underlined in the sequences overhead. The constructs are 
analyzed with pcDNA3 minigene system in HeLa cells. (B) RT-PCR performed from 
RNAs isolated from HeLa cells previously transfected with the mutated minigene. MUT22- 
24 the increase of the 3’ss strength resulted in the recovery of the exon (n=3). On the right 
hand site of the gel a schematic representation of the splicing product obtained can be
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observed. The percentage of skipping and standard deviation (SD) are indicated below each 
lane and represent the mean of three experiments.
Conversely, the bioinformatic analysis of ALPL exon 5 for putative ESEfinder elements, 
identified no predicted ESE motifs in the region corresponding to the 1st and 2nd ESE in the 
exon 4. This finding could be due to the fact that the 3’ splice site of the ALPL is well 
defined, as shown by the bioinformatic prediction that reported indeed an optimal 
consensus score.
To investigate the influence of a strong 3’ ss strength on ALPL exon 5 splicing, I generated 
a minigene where I exchanged the 3’ss of ALPL with the weaker one of ALPP (Fig. 
3.17A). Transfection and RT-PCR of this minigene, confirmed that the absence of ESE 
sequences in ALPL exon 5 as a partial exon 5 skipping when the 3’ss is weakened, can be 
observed (Fig. 3.17B). These results indicate that well defined 3’ss in ALPL exon 5 might 
not require the presence of additional c/s-acting elements, such as ESEs, to be efficiently 
recognized by the splicing machinery, whereas reducing the 3’ss strength of ALPL, the 
exon 5 is no more able to correctly include the exon in the mature mRNA.
87
A
Weak 3’ss
g c tc a g a g tg tc tc tg tc c c c a g /A C A T A C A A T  G A T A  N Q C N T T R G
--------------------------------------------- <------------------- WT.GGAGCCACAGC AACCAGTGCAACACGACACGCGGC
_________________ i
ALPP  ^  | 1“ESE t 12KdESE t I---------
Exon 4
Strong 3 ’ss A G T A  S R C N T T Q G
tg a c c c tc c tc tc c c a c c tg c a g /A C G T A C A A C  v tT .GCCGGCACCGC TCCCGGTGCAACACCACCCAGGGG
^ p L   1 j^ e q  [ I
Exon 5
MUT25. Weak 3’ss
B
% of exon o 49 7
skipping
S.D. +/- 0 0.7
ALPL
WT MUT25
Figure 3.17. Analysis of ALPL exon 5 splicing after swapping of strong 3’ss with the 
weaker one of ALPP exon 4. (A) A schematic representation of the central part of the wt 
ALPP and ALPL constructs, the exon of interest is shown in green and its flanking intronic 
region as black line and the investigated wt sequences are represented above the exon (1st 
and 2nd seq in ALPL exon 5; 1st and 2nd ESE in ALPP exon 4). The sequences reported 
nearby the mutant (MUT25) show the substitution performed on the minigene. The exact 
exchanged sequences of both ALPP 3’ss (pink) and ALPL 3’ss (blue) is reported in full. 
The constructs are analyzed with pcDNA3 minigene system in HeLa cells. (B) RT-PCR 
performed from RNAs isolated from HeLa cells previously transfected with the mutated 
minigene. RNA splicing variants corresponding to ALPL exon 5 inclusion and exclusion 
are shown. In MUT25 the weakness of the 3’ss strength resulted in a partial exon 5 
skipping. The percentage of skipping and standard deviation (SD) are indicated below each 
lane and represent the mean of three experiments.
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3.3 Testing the biochemical effect of the amino acid differences within the 
enhancer elements of PLAP and corresponding region of TNAP
I have thus far mapped the nucleotides associated with two ESEs in ALPP and the 
lack of it in ALPL linked also to amino acid differences between PLAP and TNAP (at 
protein level) in a region that is conserved at the amino acid level among the alkaline 
phosphates asides TNAP. This fine mapping of the ESEs, was crucial in order to investigate 
if the need of ESE could dictate the amino acid code in such a way as to affect protein 
function.
In order to test this hypothesis I decided to investigate if exchanging the amino acids 
encoded by the nucleotides that were shown to be part of ESE motifs, into those of TNAP 
protein would have biochemical consequences.
In the work described above I demonstrated that in the 1st ESE region the two triplets GCC 
and GGC and in the 2nd ESE region the CAG triplet, (Fig. 3.12-3.13, nucleotide differences 
in ALPL are underlined) encoding for Gly93, Ala94 and Argl25, respectively, were 
associated with ESE function as well as causing amino acid differences between PLAP and 
TNAP protein.
Intriguingly, the analysis of 3D structure (made by Prof. JL Millan’s Lab) in figure 3.18, 
modulated on the basis of human PLAP crystal structure (Le Du et al., 2001) highlighting 
the PLAP active site, shows that the amino acids of interest that differ between PLAP and 
TNAP, in the predicted ESEfinder motifs, may play a role in the catalytic protein function, 
for the proximity to the active site.
In particular, the figure 3.18A highlights the amino acid differences encoded by the 1st ESE, 
the G93 and A94 that are depicted as sticks in light blue and blue, respectively. The 
tridimentional structure showed that Gly93 and Ala94, besides being near the active site, 
are close to the conserved Ser92 residue, which is phosphorylated in the course of the 
catalysis. Figure 3.18B highlights the amino acid difference encoded by the nucleotides
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encoding within the 2nd ESE, R125 depicted as stick in purple. Also in this case the 
proximity of the amino acid to the active site, suggests a possible involvement in the protein 
activity.
A
B
Figure 3.18. Active site region of human PLAP. The highlighted residues are those that 
differ between TNAP and PLAP, within the 1st ESE, in light blue G93 and in blue A94 (A) 
and 2nd ESE, in violet R125 (B). PLAP is shown as a ribbon and investigated residues as 
sticks. The zinc atoms are shown in turquoise, the magnesium is in green, and the 
phosphate moiety is shown in orange and red. The figures were produced made by JL 
Millan’s Lab.
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3.4 Setup of methodology for recombinant Human Alkaline Phosphatase 
protein expression
In order to test the biochemical effect of the amino acid differences I initially set up a 
methodology for the production of recombinant ALPs. I decided to use a mammalian 
expression system in order to ensure the post-translational modifications on the protein 
were taking place correctly. To simplify the recovery and the purification of the 
recombinant enzymes, the GPI anchoring signal peptide sequence of ALPs was replaced by 
the FLAG octapeptide (DYKDDDDK) (Fig 3.19A). The recombinant proteins were thus 
expressed as secreted, epitope-tagged enzymes. Previous studies have demonstrated that the 
addition of FLAG tag does not interfere with the kinetic properties of the enzymes (Di 
Mauro et al., 2002). It should be stated that we opted for FLAG sequence and not for the 
more widely used His-tag system out of concern that the high affinity of this extraneous 
stretch of His residues would interfere with the binding of Znl and Zn2 in the active site 
pocket of the enzyme. Instead, the usage of secreted FLAG enzyme was widely adopted for 
a large number of ALP studies.
The expression vector pcDNA3.1 carrying the wild type PLAP and TNAP cDNA was 
kindly donated by JL Millan (Sanford-Bumham Medical Research Institute, USA). The 
FLAG epitope was introduced after Leu489 and Thr483 in TNAP and PLAP, respectively, 
followed by a termination codon to eliminate the glycosylphosphatidylinositol-anchoring 
signal (Fig. 3.19, red lettering). Since the original wt constructs showed several 
polymorphisms that altered the coding sequence, we decided to mutate these sites into wt 
(non-polymorphic) sequences to resemble a more physiological context.
The constructs were transfected into COS-1 cells for transient expression as described in 
Materials and Methods (session 6.17). Transfected cells were cultured in OPTI-MEM 
serum free medium, and conditioned media, containing secreted enzyme, was collected 48 
hours after transfection.
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Figure 3.19. Recombinant Human Alkaline Phosphatase protein expression. (A) Schematic 
representation of Alkaline Phosphatase, indicating the glycosylphosphatidylinositol (GPI) 
anchor and the soluble form after GPI substitution with FLAG epitope. (B) Complete amino 
acid sequence of human tissue non-specific (TNAP), placental (PLAP), highlighting in 
purple the residues that are removed from the C-terminus and substituted with FLAG 
epitope (DYKDDDDK).
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3.4.1 Purification and quantification of wt FLAG secreted protein
The wt PLAP-FLAG construct was used to set up a system for the purification and 
quantification of the recombinant proteins. After transfection, affinity purification of the 
soluble protein was carried out with anti-FLAG M2 monoclonal antibody affinity gel 
(SIGMA) as described in the Materials and Methods. Bound protein was eluted with five 
fractions of 1 ml glycine (100 mM, pH 3.5) (Fig. 3.20A). Only the first elution fraction of 
wt PLAP-FLAG sample exhibited a single band at approximately 64 kDa (Fig. 3.20A, Lane 
1), corresponding to the subunit molecular weight of Placental Alkaline Phosphatase 
(Greene and Sussman, 1973).
Subsequently this was also done for TNAP and in order to assess the efficiency and purity 
of this procedure, 50pi of eluted wt PLAP-FLAG and TNAP-FLAG proteins were analyzed 
by Coomassie staining and Western blot procedure (Fig. 20B and C). As shown in Figure 
19B, only a 64 kDa band, corresponding to the recombinant wt PLAP-FLAG protein was 
detected when the elutes were analyzed by Coomassie staining (Fig. 3.20B, line 1). Western 
blot analysis with an antibody anti-FLAG however showed the TNAP protein to be present 
albeit in a reduced amount (Fig. 3.20C).
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Figure 3.20. Purification of the FLAG secreted enzymes. After 48 hours from transfection, 
the culture medium is collected and the flag tagged protein is purified by anti-FLAG M2 
resin. (A) 5% of each elution fraction of wt PLAP-FLAG loaded on 10% SDS PAGE gel 
stained with Coomassie Blue. (B) 5% of the first elution fraction of wt PLAP and TNAP 
loaded on 10% SDS-PAGE gel after purification and stained with Coomassie Blue. (C) 
Western Blot of the wt PLAP and TNAP eluted proteins, using the same protein amount as 
in B experiment.
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3.4.2 Evaluating purification yield
Since this severe decrease in TNAP protein production could generate difficulties in 
quantification, essential for the measurement of enzymatic activity, the first problem to 
solve was to calculate the protein concentration.
Several approaches were investigated simultaneously to quantify the amount of the purified 
proteins. As can be seen in figure 3.21 where I approximately calculated the PLAP-FLAG 
concentration from BSA scale (~ 5ng/pl) whereas the purity of the proteins is extremely 
high the expression level is quite low making quantification by Bradford protein assay 
unfeasible. For this reason I tried to calculate the protein concentration with Micro 
Bicinchoninic Acid (BCA) Protein Assay (Pierce) for determining the protein concentration 
of dilute samples (0.5 - 20pg/mL). The amount of protein present in a solution can be 
quantified by measuring the absorption spectra and the standard curve is obtained by 
plotting the absorbance (Abs) versus known concentration of standard protein. 
Unfortunately, also micro BCA assay failed to evaluate protein yield, as the elution buffer 
that I used for purification was not compatible with this system.
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Figure 3.21. BSA concentration scale for the approximate estimation of PLAP-FLAG 
yield. SDS PAGE gel at 10% stained with Coomassie Blue in which the first five lines 
indicate the BSA concentration scale (from 25 to 200 ng) and the lane 6 shows the wt 
PLAP-FLAG in which was loaded the 5% of total protein obtained from the purification 
experiment.
I also attempted to set up an immunoenzymatic assay in order to measure the ALP catalytic
activities. This system bypasses the calculation of the protein concentration itself. The
experiments were done during a 3 weeks stage at Prof. Millan’s Laboratory, at the Burnham
Institute in San Diego. The principle of the assay, represented schematically in figure 3.22,
was based on the measurement of relative specific enzymatic activities using microtiter
plates coated with 0.2 pg/ml M2 anti-Flag. The wells were than incubated with the
recombinant enzyme carrying the FLAG epitope, recognized by anti-FLAG antibody.
When p-nitrophenyl phosphate (pNPP, 0.01-20 mM final concentration.) was added as
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substrate it is possible to measure directly the activity at 405 nm during the time (Fig. 
3.22A). For the calculation of catalytic rate constants (kcat), the wt PLAP-FLAG construct 
with a known kcat is used as a reference for each microtiter plate. Although, this system has 
been extensively used in Prof. Millan’s Lab for the measurement of enzymatic activity 
when I analyzed our wt PLAP and TNAP-FLAG enzymes, changing the missense- 
polymorphic sites into wt (non-polymorphic) sequences, with this procedure it 
unfortunately did not yield results (Fig. 3.22B). One explanation was that the changes in the 
original wt cDNA construct caused a reduction in production levels compared to the 
original one used in the laboratory (section 2.4), making impossible the measurement of the 
activity with this system. A more sensitive substrate was also tested to detect the enzymatic 
reaction: CDP-Star (phenylphosphate substituted 1,2 dioxetane) chemiluminescent 
substrate. It enables extremely sensitive and fast detection of enzymatic dephosphorylation 
by producing visible light at 466 nm. However even using chemiluminescent substrate did 
not improve the detection of catalytic activities.
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Figure 3.22. ALPs Immunoenzymatic assay (IEA). (A) Schematic representation of IEA 
used in JL Millan’s lab. 1 .Mictrotiter plates were coated with anti-FLAG antibody. 
2.Recombinant ALP-FLAG proteins were incubated with the plates for 2 h, after which 
each well was washed with PBS. 3-4. The activity of bound enzymes was than measured at 
405 nm as a function of time, after addiction of the substrate (p-NPP). (B) Wt PLAP- 
FLAG and TNAP-FLAG activity measured at 405 nm during the time.
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Finally, a quantitative slot blot assay was developed to calculate the protein concentration, 
which together with scanning densitometry allows protein detection with high sensitivity 
(Zhu et al., 2005). Amino-terminal FLAG-Bacterial Alkaline Phosphatase (BAP-FLAG) 
fusion protein was used as a standard. Figure 2.23 (A and B) shows a typical analysis of 
FLAG-BAP standard with recombinant ALP proteins detected with slot blot system. Seven 
two-fold serial dilutions of FLAG-BAP standard protein and purified enzymes were 
prepared with PBS. The BAP-FLAG standard dilutions ranged from 3.5 to 225 ng (Fig. 
3.23 A, lanes 1 and 2). The scanned image of the film and the intensity of each band on the 
slot was measured with ImageJ64 Software. Thus each peak in the graph represented a slot 
containing detected protein (Fig. 3.23B). Standard curves were obtained by plotting peak 
area versus known concentration of BAP-FLAG and fitting the data points with linear 
regression equation (Fig. 3.23C). Notably, the regression curves obtained always had good 
correlation coefficients (R2) of 0,9907 (n= 12). The peak areas of the serially diluted 
purified protein samples that fell within the detection range of each respective standard 
curve were used to calculate the protein concentration. The mean value of 3 peaks from 
each protein dilution series was used per assay with a coefficient of variation (CV) that 
ranged from 3% to 12%. PBS control samples gave no measurable signals on the 
membranes (data not shown).
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Figure 3.23 Slot blot detection of ALPs using anti-FLAG antibody. (A) Lanes 1 and 2 
contain BAP-FLAG standard, with the first (top left) slot loaded with 225 ng and followed 
by 2-fold serial dilutions. Lanes 3-4 contain purified recombinant wt PLAP-FLAG protein. 
Lanes 5-6 contain purified recombinant wt TNAP-FLAG protein. (B) A typical analysis of 
FLAG-BAP standard and recombinant ALP proteins in which the ImageJ64 Software was
y = 25578x  
R? = 0,993
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used to determine the density of the slot blot signals from a scanned image of the film. Thus 
each peak in the graph represented a slot containing detected protein. (C) Data are plotted 
as peak area versus known concentration of BAP-FLAG and fitting the data points with 
linear regression equation.
3.5 Construction of protein expression vectors by site-directed 
mutagenesis of PLAP cDNA
To establish if the amino acid differences between PLAP and TNAP associated with 
ESE, in the former, may play a role in PLAP function I decided to test whether they have a 
biochemical effect by mutating them for the corresponding amino acids in TNAP.
The 1st ESE region in PLAP contains the amino acids Gly93 and Ala94 (Fig. 3.24A). I 
mutagenized these two amino acids to the corresponding residues in TNAP, i.e., Ala and 
Gly, respectively, in the context of wt PLAP-FLAG cDNA, creating a new construct: 
PLAP-FLAG 1st ESE [G93A; A94G] (Fig. 3.24C). In the 2nd ESE region the amino acid 
difference between PLAP and TNAP found to be associated with the ESE was Argl25 (Fig. 
3.13). This was therefore mutated to the corresponding residue in TNAP, i.e., Gin, in the 
context of wt PLAP-FLAG cDNA giving rise to the new expression construct: PLAP- 
FLAG 2nd ESE [R125Q] (Fig. 3.24C). The results previously observed in the figure 3.17 
demonstrated that the amount of ALPP exon 4 skipping increases drastically when both 
ESE sequences were substituted for the corresponding region of ALPL, suggesting that they 
can act in a synergistic manner. Based on this finding, I also created a mutant in which 
residues encoded by the 1st and 2nd ESE region in PLAP, i.e. Gly93, Ala94 and Argl25 
were mutagenized into the corresponding amino acids of TNAP, Ala, Gly and Gin, 
respectively generating the mutant PLAP-FLAG l st/2nd ESE [G93A; A94G; R125Q] (Fig. 
3.24C).
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PLAP-FLAG 2nd ESE [R125Q]
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PLAP-FLAG 1st ESE/2nd ESE [G93A;A94G;R125Q]
...TYNVDKHVPDSAGTATAYLCGVKGNFQTIGLSAAARFNQCNTTRGEVISVMNRAKKA.^
Figure 3.24. Comparison between PLAP and TNAP amino acid sequence in a region that 
includes the ESE sequences. (A) The region enclosed by the grey box highlights the amino 
acids that differ between PLAP and TNAP within the 1st ESE and corresponding nucleotide 
variations. (B) The region enclosed by the grey box highlights the amino acid that differs 
between PLAP and TNAP within the 2nd ESE and corresponding nucleotide variations. (C) 
Partial amino acid sequence of PLAP mutants. Amino acid changes are highlighted in 
turquoise.
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Cosl cells were transfected with the mutated construct. The conditioned media, containing 
secreted mutant enzymes, was collected 48 hours after transfection and then purified using 
the anti-FLAG M2 gel. The mutated purified proteins was subjected to 10% SDS-PAGE 
stained with Coomassie blue. This analysis revealed that the production of PLAP-FLAG 1st 
ESE [G93A; A94G] is approximately the same obtained for the recombinant wt PLAP- 
FLAG protein whereas that of PLAP-FLAG 2nd ESE [R125Q] and PLAP-FLAG 1st /2nd 
ESE [G93A; A94G; R125Q] was only approximately 50% of that was obtained for the wt 
enzyme (Fig. 3.25).
Not withstanding these low levels of expression I was able, using the quantitative slot blot 
assay, to calculate the protein concentration, loading much more quantity of PLAP-FLAG 
2nd ESE and PLAP-FLAG 1st /2nd ESE through the slot to obtain a good signal on the 
membrane.
•> JS- oN sX sv ,<N
64 —  
kDa
1 2  3 4
Figure 3.25. An example of SDS PAGE gel at 10% stained with Coomassie Blue. 
Controlling the purity production of recombinant proteins. In each case the 5% percent of 
the first elution was loaded.
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3.6 Kinetic studies of ALPs
To study if the differences in the amino acid sequence in the 1st and 2nd ESE of 
PLAP, compared to the corresponding region in TNAP, which I hypothesized to be related 
to the need of splicing regulatory elements in these areas, could affect the kinetics of the 
protein, I tested if these changes affect PLAP through an enzymatic assay to measure the 
kinetics of this protein based on the following reaction:
o
2 ON ^  ^  o  P O' + H20
o*
p-Nitrophenol Phosphate O
20N ^-------OH + ‘o ------ p----- O'
O'
p-Nitrophenol Phosphate
(yellow)
The enzymatic reaction consisted in the removal of a phosphate from the p-NPP, used as 
substrate, to generate p-nitrophenol. While the substrate, pNPP, is colorless, the product p- 
nitrophenol is yellow, so it was possible to follow the reaction progress by measuring the 
generation of yellow color. Hence, the rate of the enzyme-catalyzed reaction can be traced 
by taking absorption readings of the amount of product accumulated at 405nm as a function 
of time.
Initially to set up the system I tested wt PLAP and TNAP-FLAG constructs. Enzyme 
kinetic determinations of wt ALP proteins were performed in microtiter plates by adding 
the enzyme to pNPP in 1.0 M diethanolamine (DEA) buffer, pH 9.8 (see materials and 
methods). The substrate concentration was varied between 0.01 and 20 mM with eleven 
different enzymatic reactions for each wt enzymes. The assay mixture also contained 
MgCL and ZnCh because each catalytic site contains three metal ions, i.e., two Zn and one
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Mg, necessary for enzymatic activity.
The ALP reaction proceeded following Michaelis-Menten kinetics. In order to evaluate the 
catalytic parameters I calculated initial velocity (v0) for each different substrate 
concentration. An important assumption is that the concentration of enzyme-substrate 
complex ([ES]) should remain unchanged during the initial velocity measurement, hence 
when the absorbance increases at a linear rate. The terminology describing this phase is 
“steady-state”, because the concentration of ES is steady during the time interval used for 
enzyme kinetic work.
The initial rate of reaction was evaluated simply as a change in absorbance per unit of time: 
for pNPP formation this would be A^s/min, related to an increase in the concentration of 
the product, p-nitrophenol, per minute (Ac/min). The corresponding Ac/min was determined 
using Beer-Lambert’s law, converting the absorbance value to the actual p-nitrophenol 
formed per minute. The reaction was followed for lh  but the v0 was calculated only from 
the linear part of the time-curve, generally 15 min (Fig. 3.26).
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Figure 3.26. An example of p-nitrophenol formation measured as an increase in absorbance 
at 405 nm (Abs 405) during the time A ^/m in (15 min). Eight ng of enzyme preparation 
were added to 200 ul of DEA buffer containing different concentration of p-NPP (sl-11), 
i.e., sl contained 20mM and followed by 2-fold serial dilutions.
Since the best way for the measurement of catalytic activities is to fit a hyperbola directly to 
the substrate-velocity data, for this reason I used Prism program that automatically 
computed the binding parameters. Hence, the substrate concentration ([S]) on the x axis was 
plotted against the initial velocity (v0) on the y  axis, and the data were fitted in Michaelis- 
Menten equation. Four parameters were obtained from the Michaelis-Menten equation: (1) 
Vmax is the maximum rate that can be achieved at a given concentration of enzyme; (2) Km, 
the Michaelis constant, which is defined as the substrate concentration that produces an
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initial velocity equal to one-half of Vmax and is a measure of the affinity for the substrate; 
(3) Kcat, the enzymatic turnover number, which gives the frequency with which an enzyme, 
operating at saturation, can convert substrate to product; (4) Kcat/Km that considers how 
well the substrate is bound to the enzyme and how rapidly it is converted from that point on 
to product.
Analysis of catalytic values for wt PLAP and TNAP are presented in Table 3.1. From our 
biochemical study, and in accordance to what is already known in literature, the Vmax of 
TNAP was found to be double that of PLAP due to a more rapid movement of substrate 
into and out the active site, instead PLAP has a greater affinity for the substrate with a 
consequent lower Km value (Fig. 3.27). These differences can be better observed visually in 
the Lineweaver-Burk plot where I transformed the data to double reciprocal plot (1/[S] vs. 
l/v0) that was linear over the range of substrate concentration used, as shown in figure 3.27B. 
The determined kinetic parameters are listed in the Table 3.1.
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Figure 3.27. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis of p- 
NPP by wt PLAP-FLAG (A ) and wt TNAP-FLAG ( • ) .  Eight ng of enzyme preparation 
were added to 200 ul of DEA buffer containing different concentration of p-NPP (from 0.01 
to 20 mM). (A) The initial velocities (v0) were related to the concentration of substrate, [S], 
and the data were fitted in Michaelis-Menten equation. (B) In the Lineweaver-Burk plot the 
data were transformed to double reciprocal plot (1/[S] vs. 1/vo) that was linear over the 
range of substrate concentration used.
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3.6.1 Effect of GIy93>Ala and Ala94>GIy amino acid substitutions on the kinetic 
activity of PLAP.
After setting up the kinetic assay and the purification of the proteins, I tested 
whether substituting the amino acids encoded within the 1st ESE for the residues found in 
TNAP, (Gly93 and Ala94 for Ala and Gly) would have any functional effects on catalysis. 
To verify this possibility, I compared wt PLAP-FLAG and PLAP-FLAG 1st ESE mutated 
[G93 A; A94G] enzymatic kinetic parameters.
The best-fit values, from Michaelis-Menten equation, for the kinetic constants revealed a 
significant difference, between the wt PLAP-FLAG and 1st ESE mutated recombinant 
enzymes, in their affinity for the substrate (Fig. 3.28A). Indeed, Km values were 0.2239 ± 
0.017 mM and 0.1519 ± 0.015 mM, respectively (p <0.01) (Fig. 3.30). This difference can 
better be visually appreciated in the Lineweaver-Burk plot where I transformed the data to 
double reciprocal plot (1/[S] vs. 1/vo) that was linear over the range of substrate 
concentration used, as shown in Fig. 3.28B. The decrease in Km was not accompanied by 
any significant variation in Vmax and consequently in Kcat between the two enzymes. Data 
from wt and 1st ESE enzymes showed normal distribution. The statistical significance was 
evaluated using Students t-test. The kinetic parameters are listed in the Table 3.1.
Taken together these findings suggest that when specific residues in the 1st ESE, i.e., G93 
and A94 are mutated for that of TNAP an increase in substrate-binding affinity to the 
catalytic site of the enzyme occurs, consistent with selection towards a more favourable 
amino acid content after release from splicing-related constrain. However, the observed 
difference in the Km or Vmax of mutant enzymes in which the amino acids in the region of 
the ESE where substituted for those of the TNAP could take a different direction respect to 
the original TNAP protein activity. This was observed with the substitution of Ala93Gly 
and Gly94Ala in PLAP 1st ESE mutated enzyme that showed an increase in the affinity for 
the substrate (Km= 0.1519 ± 0.015) compared with wt TNAP (Km= 0.4365 ± 0.05). Several
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reasons can explain this behaviour, firstly it is important to keep in mind that the 
identity between the two enzymes is approx. 50%, hence, mutating the amino acids of 
PLAP, corresponding to the ESE region for that of TNAP, does not necessarily mean that 
the Km and Vmax of PLAP will become more TNAP. Secondly although the residues 
involved in the active site and those coordinating the two zinc atoms and magnesium ion 
are largely conserved among the family, any amino acid change in the active site could 
change the conformation of the binding-pocket altering the catalytic properties in an 
unpredictable way. The important conclusion from these experiments is that introducing 
residues present in TNAP, where the selection at the splicing level did not occur because of 
the presence of strong 3’ss, in the context of PLAP it was possible to release just a portion 
of this protein from splicing-related constrain, allowing a better performance.
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Figure 3.28. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis of p- 
NPP by wt PLAP-FLAG (A ) and PLAP-FLAG 1st ESE mut [G93A;A93G] (*). Eight ng 
of enzyme preparation were added to 200 pi of DEA buffer containing different 
concentration of p-NPP (from 0.01 to 20 mM). (A) The initial velocities (v0) were related to 
the concentration of substrate, [S], and the data were fitted in Michaelis-Menten equation. 
(B) In the Lineweaver-Burk plot the data were transformed to double reciprocal plot (1/[S] 
vs. 1/vo) the Y-axis and X-axis interceptions represent 1/Vmax and -1/Km respectively.
I l l
3.6.2 Effect of Argl25>Gln amino acid substitution on the kinetic activity of PLAP
The PLAP-FLAG 2nd ESE [R125Q] enzyme was also tested for its activity. As in 
the previous experiment the initial velocities were plotted against the different 
concentrations of pNPP and values for the kinetic parameters Vmax and Km were derived 
by fitting data directly to the Michaelis-Menten equation (Fig. 3.29A)(GraphPad Prism
2.0). To analyze a possible effect of this mutation on enzymatic activity, I compared the 
Vmax, Km, and Kcat of the mutant enzyme to the wt. The best-fit values for the kinetic 
parameters revealed a significant difference, between the wt and 2nd ESE mutant 
recombinant enzymes, in their maximal rate. Indeed, Vmax were estimated to be 0,07512 ± 
0,001181 s'^pM and 0,1030 ± 0,001 s'^pM, respectively (p <0.001) (Fig. 3.31). 
Accordingly, the mutant enzyme showed higher Kcat (329.6 ± 0.0009 s'1) than PLAP wt 
(240.4 ± 0.001 s'1) and consequently higher Kcat/Km value (1.543 s'^pM '1). The increase in 
Vmax, and consequently in Kcat, was not accompanied by any significant variation in Km 
(Table 3.1). Even data from 2nd ESE mut [R125Q] enzyme showed normal distribution. The 
statistical significance was evaluated using Students t-test.
Also for PLAP-FLAG 2nd ESE [R125Q] enzyme, I transformed the data to Lineweaver-Burk 
plot (1/[S] vs. l/v0), as shown in Fig. 3.29B. In Lineweaver-Burk plot, the Vmax values were 
represented by y-intercept of the graph (1/Vmax) but the differences were graphically less 
pronounced than in the Michaelis-Menten plot.
These findings indicate that when the amino acid R125, associated with ESE function in the 
2nd ESE region, is mutated for that of TNAP the consequence in protein function is a more 
rapid movement of substrate into and out the active site increasing the maximal rate and the 
catalytic efficiency of the enzyme.
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Figure 3.29. The Michaelis-Menten and Lineweaver-Burk plots for the hydrolysis of p- 
NPP by wt PLAP-FLAG (A ) and PLAP-FLAG 2nd ESE mut [R125Q] (♦ ) .  Eight ng of 
enzyme preparation were added to 200 |il of DEA buffer containing different concentration 
of p-NPP (from 0.01 to 20 mM). (A) The initial velocities (v0) were related to the 
concentration of substrate, [S], and the data were fitted in Michaelis-Menten equation. (B) 
In the Lineweaver-Burk plot the data were transformed to double reciprocal plot (1/[S] vs. 
1/vo) the Y-axis and X-axis interceptions represent 1/Vmax and -1/Km respectively.
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3.6.3 Effect of Gly93>Ala, AIa94>Gly and Argl25>Gln amino acid substitutions on the 
kinetic activity of PLAP
To further analyze the possible synergic role played by A93G/G94A and R125Q, in 
the phosphatase activity of PLAP, I expressed an engineered double mutant enzyme the 
PLAP-FLAG 1st /2nd ESE mut [A93G; G94A; R125Q]. When the recombinant enzyme was 
tested for its activity mutation of these three amino acids in PLAP clearly affected alkaline 
phosphatase catalysis in PLAP-FLAG 1st /2nd ESE mut [A93G; G94A; R125Q], abrogating 
the activity altogether.
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Figure 3.30. Box-plot showing the Michaelis-Menten constant (Km) in wt PLAP-FLAG, 
PLAP-FLAG 1st ESE mut [A93G; G94A], PLAP-FLAG 2nd ESE mut [R125Q] and PLAP- 
FLAG 1st /2nd ESE mut [A93G; G94A; R125Q]. Middle horizontal line inside box indicates 
median. Bottom and top of the box are 25th and 75th percentiles, respectively (n=6).
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Figure 3.31. Box-plot showing the maximal rate of reaction (Vmax) in wt PLAP-FLAG, 
PLAP-FLAG 1st ESE mut [A93G; G94A], PLAP-FLAG 2nd ESE mut [R125Q] and PLAP- 
FLAG 1st /2nd ESE mut [A93G; G94A; R125Q], Middle horizontal line inside box indicates 
median. Bottom and top of the box are 25th and 75th percentiles, respectively. The outliers 
are represented as circles and are the points beyond the lower and upper extreme values of 
the box plot (n=6).
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TABLE
Kinetic Parameters o f ALP and Mutants
pNPP
Enzyme --------------------------------------------------------------------
Alkaline
Phosphatase (ALP) Km Vmax Kcat Kca/K m
(mM) (pMs ) (s 1) (s pM  )
Wt PLAP-FLAG 0.2239 ±0.017 0,07512± 0,0011 240.4 ±0.001 1.073
Wt TNAP-FLAG 0.4365 ±0.05 0,1719 ±0,005 573 ±0.0013 1.312
PLAP -FLAG
1st ESE [G93A;A94G] 0.1519 ± 0.015 0,06637 ±0,0013 212.4 ±0.0013 1.398
PLAP-FLAG
2nd ESE [R125Q] 0.2135 ±0.009 0,1030 ±0,001 329.6 ±0.0009 1.543
PLAP-FLAG
1st ESE [G93A;A94G] ND ND ND ND
/2nd ESE [R125Q]
Measurements were done at pH 9.8 using pNPP as substrate in the presence o f 1 mM o f MgCl2 and 20pM  
o f ZnCl2.
Table 3.1. Kinetic parameters of ALP and mutants. The difference in the Km or Vmax of 
mutant enzymes in which the amino acids in the region of the ESE where substituted for 
those of the TNAP could take a different direction respect to the original TNAP protein 
activity, as observed with PLAP 1st ESE mutated enzyme that showed an increase in the 
affinity for the substrate (Km) compared with wt TNAP.
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4. DISCUSSION
The existence of exonic splicing enhancers (ESE) is well established and confirmed by 
many reports through over two decades of research. In fact, it has been demonstrated that 
ESEs participate in exon recognition, controlling both alternative and constitutive splicing 
processes (Wang and Burge, 2008) and that their presence is widely distributed among 
eukaryotic organisms, having a very early evolutionary origin (Webb et al., 2005). The fact 
that ESE-mediated splicing was an early phenomena in eukaryotic organisms makes for 
fascinating implications with regards to the potential relationships between coding and 
splicing regulatory regions during the course of evolution.
Although it is plain that these ESE overlap with coding capacity, the effect of the conflict 
between ensuring splicing efficiency and preserving the coding capacity has not been 
specifically analyzed. The impact that the double purpose of the coding sequence might 
have on gene evolution is that proteins may not be as optimised as they could be, due to the 
fact that their sequence has to comply with possible conflicting functions: the pressure to 
maintain the exon included in the mature mRNA and the selection of sequence variants that 
encode amino-acids that enhance the particular protein function. The former selective 
pressure might be more important than the latter, because exon inclusion in the final mRNA 
is a pre-condition for its translation (Pagani and Baralle, 2004). Consequently, this suggests 
that any amino acidic substitution should be selected also at splicing level in order to occur 
and confer particular advantages to protein performance.
In keeping with this concept, as already mentioned in the introduction, several studies have 
uncovered the presence of extensive purifying selection against substitutions in ESE as 
determined by a strong bias in codon choice at the intron-exon junction, with codons 
favoured in known ESEs found in the boundaries (Parmley et al., 2007).
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Selection operating on splice control elements is further supported by the rarity of SNPs 
(single-nucleotide polymorphisms) density in these regions, this owing to the need to 
preserve their function (Carlini and Genut, 2006; Fairbrother et al., 2004a). Analogously, 
analysis of retrogenes in which the residues located in the original parental copy were at the 
intron-exon junctions showed that they have a higher rate of evolution. This suggest that 
constraints exist near intron-exon borders that have been released in the retrogenes and the 
higher rate of evolution in these sites is coherent with selection towards a more favourable 
amino acid content after release from splicing-related selection (Parmley et al., 2007). 
However it should be kept in mind that in these studies the presence of the ESE were only 
hypothetical and caution should be employed when making these kind of comparisons on 
the basis of bioinformatic studies (Irimia et al., 2009). For this reason, it is better to support 
any eventual conclusion with functional experiments that might either sustain or not the 
bioinformatics considerations. At the experimental level, the observation that splicing is 
subject to intense selective pressure during the course of evolution has been shown to occur 
in several exons such as CFTR exon 9 and 12 and fibronectin EDA exon (Haque et al., 
2010; Pagani et al., 2005; Pagani et al., 2003a; Zago et al., 2011). The effect on the splicing 
efficiency indicates that exonic sequences are significantly constrained by splicing 
requirements that in turn restrict evolutionary productive genome variability. Therefore 
missense mutation can segregate in human population during the evolution and can be 
responsible of deleterious effects on protein function and the fate of this change may be the 
elimination by purifying selection (Hellmann et al., 2003) or the maintenance to preserve a 
proper exon inclusion.
Since several studies have been performed on the possible evolutionary connections 
between coding capacity and splicing regulation in different species it was also interesting 
to analyze how splicing regulatory elements evolve in the human genome, and how they 
behave in gene duplication events. Duplicate genes arise frequently in eukaryotic genomes 
and generally undergo accumulation of mutations. Because deleterious mutations occur
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much more frequently than beneficial ones there is a higher probability that these mutations 
lead to loss of function of one gene copy, becoming pseudogenes. Nevertheless, it is also 
possible that duplicate genes are preserved for long time periods, even if the mechanism is 
still unclear. In addition to the classical model for the evolution of gene duplicates, in which 
the only mechanism by which a duplicate gene can be preserved is the acquisition of new 
beneficial function (Ohno, 1970) an alternative model was proposed by Force et al. (Force 
et al., 1999). In this model gene duplicates are frequently preserved by subfunctionalization 
in which complementary degenerative mutations in different regulatory elements of 
duplicated genes can facilitate the preservation of both duplicated genes and after these 
mutations each daughter gene adopts part of the functions of their parental gene. Indeed, 
several observations indicate that a common fate of the members of duplicate-gene pairs is 
the partitioning of tissue-specific patterns of expression of the ancestral gene that might 
reduce the pleiotropic constraints (Lynch and Force, 2000).
In this thesis I have attempted to address the question whether the presence of ESEs 
conditioned the coding capacity in human genes by investigating the evolutionary 
constraints of ESE sequence maintenance on the enzymatic activity of the paralogous ALP 
protein family.
4.1 ESE Analyzer Web Server (EAWS) computational analysis. 
Identifying a candidate paralogous protein family
In the first part of this study a bioinformatic platform ESE Analyzer Web Server 
(EAWS) was developed in collaboration with Dr. Vlahovicek (University of Zagreb, 
Croatia), and used for the identification of candidate protein families in which the evolution 
of mRNA sequences was conditioned by the presence of exonic cis-acting splicing 
regulatory elements. These elements encode also for amino acid that, even if sub-optimal 
for protein function, were maintained in the course of evolution most likely only to ensure a
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correct splicing. In particular EAWS is able to integrate information from different sources 
available to date regarding splicing from the existing web servers (i.e., Gene Splicer, FAS- 
ESS, ESE RESCUE, ESEfinder). It also allows, at the same time, to align transcripts and 
protein sequences of similar functional domains and in particular in this study I looked at 
human paralogous gene families to find out examples in which the need for ESE may 
influence the protein activity of evolutionary correlated proteins (paralogs).
By using this platform, the most promising candidate protein family were those of the 
human Alkaline Phosphatase paralogous genes (ALPs; Fig. 3.5) in which the need for ESE 
has influenced the codon choice, protein activity and most likely the evolution of this 
protein family. Specifically, the exon encoding for the active site of the enzymes showed 
compensatory changes in acceptor strength followed by changes in ESE and amino acid 
variations close to the active Serine among the paralogs.
Although not the aim of the study, this type of tool might in the future enhance the 
positive hit rate of splicing regulatory elements (SRE) predictions. This would be a useful 
tool in clinical diagnostics, especially if we consider that in study of neurofibromatosis 
typel (NFl)(Ars et al., 1999) and ataxia teleangectasia (ATM)(Teraoka et al., 1999) up to 
50 % new mutations were found to be splicing mutations and their identification as such is 
of paramount importance. Indeed, a key issue raised in molecular diagnosis is the correct 
interpretation of the biological consequences of a gene sequence variant in which the real 
disease-causing mutation has not yet been identified; e.g., their putative impact on splicing. 
Accordingly, as mentioned above several lines of evidence suggest that many unclassified 
genetic variants might turn out to result in splicing abnormalities (Baralle and Baralle, 
2005; Baralle et al., 2009).
The reason that the role of splicing mutations has been realized relatively late is 
because it has been difficult to show a clear correlation between the suspected mutation and 
disease, in contrast with other types of genetic mutation, in which this connection is 
relatively straightforward. From this exigency the usage of more reliable software to predict
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whether a given variation would interfere with mRNA splicing would be useful for genetic 
counselling in the clinic.
The EWAS platform will align paralogous genes and analyze the transcripts for the 
presence of splicing regulatory elements, this ability to integrate information from different 
sources and to fetch directly from Ensembl transcripts belonging to the same family would 
increase the ease with which to analyze such mutations. For example, if a mutation occurs 
in an area very conserved among the family members and corresponds also to a 
hypothetical ESE throughout the family most likely such mutation will be deleterious for 
the protein. EWAS also calculates splice site strength and the user could easily check in the 
user friendly output, the splice site strength of the exon within which the mutation is found. 
Since it is difficult to experimentally analyze each sequence variant that could affect gene 
function in a routine, high-throughput manner, EAWS represents an easy source for 
clinicians and researchers, and can help to save a lot of work and money, identifying the 
most likely potential disease-causing splicing mutation.
4.2 Validation of bioinformatics ESE predictions
I have used a minigene system and mutagenesis analysis to confirm the presence of 
ESEs. Our data shows that exon 4 of ALPP contains two enhancer elements (1st and 2nd 
ESE) necessary for promoting exon inclusion due to the weak upstream 3’ss (section 3.2). 
The substitution of these sequences with corresponding one of ALPL, whose nucleotide 
content is not associated with ESE function, resulted in exon 4 skipping (Fig. 3.8; 3.12- 
3.14) while improving the splice site strength exchanging the ALPP 3’ss with that of ALPL 
made ESEs superfluous (Fig. 3.15- 3.16).
On the other hand, the results of our analysis have also demonstrated that in the exon 5 of 
ALPL (corresponding to exon 4 of ALPP), the lack of ESE in the regions 1st seq and 2nd seq 
(Fig. 3.8) most probably reflect the presence of strong 3’ss, indeed in this case the exon is
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correctly recognized even in absence of splicing enhancers, conversely reducing the 3’ss 
strength, the exon 5 is no more able to correctly include the exon in the mature mRNA (Fig. 
3.17).
Taken together, these results suggest that there is a tightly regulated network between the 
strength of the splice sites and the other splicing cis-acting regulatory elements in the exons 
under study controlling the outcome of splicing event.
4.3 Testing the biochemical effect of the amino acid differences within the 
enhancer elements of PLAP and corresponding region of TNAP, the 
protein products of ALPP and ALPL respectively
As mentioned before, the realisation that ESEs overlap with coding capacity is well 
established, however the effect of ensuring splicing efficiency and preserving the coding 
capacity has not been specifically analyzed to date. In this thesis I mapped two ESEs in 
ALPP not present in ALPL. These ESEs correspond to an area that in TNAP differs in 
amino acid sequence to PLAP representing a possible splicing constraint on the enzymatic 
activity of the protein. Indeed, substituting the amino acids in the region of the ESE for 
those of the TNAP, where the ESEs are absent, highlighted a significant constraint of the 
ESE on protein function. It was then of interest to analyse the effects these substitutions had 
on the enzymatic activity of the protein. That this was indeed the case in this scenario was 
quite high as these amino acid differences were close to the Ser92, the phosphate-binding 
residue involved in the catalytic reaction as determined from inspection of the crystal 
structure of the PLAP active site. Indeed substitution of Ala93Gly and Gly94Ala in PLAP 
produced a significant increase in the affinity for the substrate compared with wt PLAP 
(Fig. 3.28; Table 3.1). The single amino acid substitution Argl25Gln in PLAP that 
corresponded to the amino acid difference in the second ESE mapped in ALPP increased 
the protein performance improving the maximal rate with a faster processing of the
substrate in the active site pocket of the enzyme (Fig. 3.29; Table 3.1). The exchange of the 
amino acids corresponding to both the ESEs resulted in the complete abolition of the 
function (Table 3.1).
These observations confirm the hypothesis that sequences that perform both coding and 
splicing regulatory functions introduce splicing-related constraints on amino acid sequences 
that may affect protein performance.
Interestingly, although this is not the aim of the study, this kind of research can also be used 
to develop proteins for gene therapy or biotechnological application. Indeed, the usage of 
modified enzyme with increased catalytic constants will allow a good employment in the 
industries where proteins with better performance respect to the native condition could find 
several applications.
4.4 Alkaline phosphatase and evolution
Current views of the evolutionary history of ALP propose that the ancestral gene 
expresses tissue-unspecific alkaline phosphatase, as for example occurs with the E. coli 
enzyme, and that the actual tissue unspecific isoenzyme that populate liver, bone, kidney 
and the first-trimester placenta (ALPL) maintains the ancestral gene’s characteristics while 
the other paralogs later acquired the tissue- specificity together with other features. Indeed, 
through a process of gene duplication and additional mutations, the intermediate intestinal 
gene arises from the tissue-unspecific precursor gene (ALPL like) and subsequently 
becomes the progenitor of intestinal, germ cell and placental genes (Fishman, 1990) (Fig.
4.1). In particular, ALPP gene represents a late evolutionary event since enzymes with the 
properties of PLAP (protein product of ALPP gene) were found expressed only in placenta 
of chimpanzee, orangutan and human (Doellgast and Benirschke, 1979) while PLAP and
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TNAP (protein product of ALPL gene) are equivalent in several other mammalian species 
(Harris, 1980). The human Alkaline Phosphatase paralogous gene family has already been 
proposed as an example of subfunctionalization since these genes are expressed in different 
tissues still preserving the same general function (Rump et al., 2001). In particular, the 
tissue specificity can be explained by different alterations in the promoter regions of the 
genes, consistent with the findings from alkaline phosphatase promoter studies (Kiledjian 
and Kadesch, 1990; Millan, 1987).
Ancestral Gene 
Tissue Unspecific Precursor Gene
Intermediate Intestinal ALP Gene
Intestinal ALP Gene 
(ALPI) T
Germ Cell ALP G ene_________
(ALPPL2)
T
Placental ALP Gene 
(ALPP)
Figure 4.1. Possible evolutionary path of the ALP isoenzymes. Figure taken from Fishman 
(1990).
The ESEs I have mapped in ALPP, that are absent in ALPL, are necessary due to a weak
3’ss in the former. Since, as mentioned at the beginning of this section, ALPL has the same
characteristics as the ancestral copy, these changes in splicing regulatory elements, within
the catalytic exon of ALPP, from ALPL (ancestral like) to ALPP (later evolutionary event)
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V
Tissue Unspecific Gene 
(ALPL)
have followed the evolutionary history of this family as summarized in the model depicted 
in figure 4.2. Specifically, after the last common ancestral gene, which accounts for ALPL 
gene, at least two hypotheses are possible to explain the temporal succession of these 
changes in splicing motifs, but of course many others are feasible. The possible pathways 
imply always gene duplication from the unique initial non-tissue specific gene (ALPL like) 
and additional mutations.
In particular, the first hypothesis (Fig. 4.2; left panel), represents a scenario where the first 
random mutations in the exon led to creation of the ESE and consequently variations in the 
amino acid sequence; these mutations would not have any consequence on the splicing but 
only possibly on the protein function since a strong 3’ss is still present. Thus any amino 
acid change that may have occurred would produce a functional protein with the 
characteristics of ALPP, hence different from the parental copy. Subsequently, the second 
nucleotide changes could occur either in the exonic region generating another ESE or 
within the 3’ ss. If within the exonic region, it would have no effect on splicing but the 
outcome would only be on protein activity (for the same reasons explained above). If, on 
the other hand, it were to occur in the 3’ ss reducing the strength I have previously 
demonstrated that with just one ESE present associated with weak 3’ splice site aberrant 
splicing would occur. However, this is only around 25 percent therefore the majority of the 
mRNA molecules can still be correctly synthesized. After that a second ESE was created by 
chance allowing the complete inclusion of the exon.
The second hypothesis (Fig. 4.2; right panel), is based on the splicing compensation model 
(Ke et al., 2008), mutation in the splice site occurred first, weakening the 3’ ss strength, 
even if we don’t know to which extent (maybe still providing partial exon inclusion), after 
that a compensation in the form of a gain of two ESEs, concurrent or subsequent, preserved 
the complete inclusion of the exon, hence, a correct splicing. However the latter alternative 
(Ke et al 2008) does not explain how the exon was maintained without drifting until the 
ESE was formed unless all the mutations, i.e. ESE and 3’ss, were simultaneous. However,
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compensatory model paints a picture of exon evolution as a dynamic interplay between 
helpful and harmful mutations, continuously at work.
Since ALPP is 90% homologous to the other two tissue specific isoenzymes most likely the 
same results obtained in ALPP would occur also in ALPPL2 and ALPI, making possible to 
extend these theory to a more general evolutionary theory of splicing motifs from the tissue 
unspecific ancestral gene to the less distant tissue specific isoforms.
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Ancestral Gene
(ALPL L ike)
tcccacctgcagACGT T
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that create the  
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M utation that 
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splice site
cm
M utation that 
w eaken the  splice  
site
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that create th e  
l st/o r  2 nd ESE
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that create the  
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□ P E —
ALPP like exon ALPP like exon
Figure 4.2. Two possible hypotheses to explain the temporal succession of changes in 
splicing motifs in the ALP tissue-specific exon 4. The hypothesis on the left represent a 
scenario where the first casual mutations generated occurs in the region of the ESE this 
casual positive event made possible second nucleotide changes that could occur either 
within the 3’ ss or in the exonic region generating another ESE. In the first case 
“degenerative” mutations that weakened the 3’ss strength, in presence of only one ESE will 
cause partial exon skipping, later on a second ESE was created by chance or, in the second 
case, firstly occurred a casual positive formation of the second ESE that allowed the 
mutations that weaken the splice site to take place, as the correct splicing was already fully 
guaranteed. Second hypothesis on the right, is based on the splicing compensation model
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(Ke et al., 2008), mutation in the splice site occurred first, weakening the 3’ ss strength, 
even if we don’t know to which extent. Subsequently compensatory changes, such as the 
creation of new ESEs, act to ameliorate the effects of the deleterious mutations and are 
positively selected.
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5. CONCLUSIONS
In conclusion, in this study I have identified a family of paralogous genes where there is 
interplay between splice site strength and presence or absence of ESE sequences. These 
ESE sequence also dictate in part the catalytic characteristics of the enzyme. The splicing 
constraints thus generated a suboptimal paralogous protein that was tolerated to allow the 
persistence of sequences that are essential for exon inclusion.
Also, this study has established experimentally that the relationship between the constraints 
of ESE sequence on amino acid variability are enough to strongly condition the evolution of 
the protein. If a certain function would be desirable for a certain physiological role of the 
protein this may not be possible unless there are other changes that can ensure a correct 
splicing of the exon.
Hence, the changes A93G, G94A and R125Q, that may improve the substrate binding 
affinity and/or enzyme kinetics in PLAP, are not compatible with enzyme function as long 
as other splicing determinants (weak splice site) are in place.
Finally it is important to note, as mentioned above, that this kind of studies are not only 
important for a general understanding of protein evolution but can also help to develop 
proteins for biotechnological application or gene therapy, where it is crucial to optimize the 
protein performance.
130
6. MATERIALS AND METHODS
6.1 Chemical reagents
General chemicals were purchased from Sigma Chemical Co., Merck, Gibco BRL, 
Boehringer Mannheim, Carlo Erba and Serva.
6.1.1 Standard solutions
All the solutions are identified in the text when used apart from the following:
a) TE: 10 mM Tris-HCl (pH 7.4), 1 mM EDTA (pH 7.4)
b) PBS: 137 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 1.8 mM KH2P04, pH 7.4
c) 10X TBE: 108 g/1 Tris, 55 g/1 Boric acid, 9.5 g/1 EDTA
d) 6X DNA sample buffer: 0.25 % w/v bromophenol blue, 0.25 % w/v xylene 
cyanol FF, 30 % v/v glycerol in H20.
e) 10X protein sample buffer: 20 % w/v SDS, 1 M DTT, 0.63 M Tris-HCl (pH 7),
0.2% w/v bromophenol blue, 20 % v/v glycerol, 10 mM EDTA (pH 7).
f) TBS: 50 mM Tris-HCl, 150 mM NaCl, 2 mM CaC12, pH 7.5
6.2 Enzymes
Restriction enzymes were from New England Biolabs, Inc. DNA modifying enzymes such 
as Taq Polymerase, DNasel RNase free, and T4 DNA ligase were obtained from Roche 
Diagnostic. Klenow fragment of E. coli DNA polymerase I and T4 polynucleotide Kinase 
were from New England Biolabs, Inc. RNase A was purchased from Sigma Chemicals Ltd. 
A 10 mg/ml solution of RNase A was prepared in sterile water and boiled for 10 minutes to
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destroy trace amounts of DNase activity. All enzymes were used following manufacturer’s 
instructions.
6.3 Synthetic oligonucleotides
Synthetic DNA oligonucleotydes were purchased from Sigma-Genosy and IDT (Integrated 
DNA Technologies).
6.4 Bacterial culture
The E. Coli K12 strain DH5a was transformed with the plasmids described in this study 
and used for their amplification. Plasmids were maintained in the short term as single 
colonies on agar plates at 4 °C but for long term storage they were kept on glycerol stocks 
made by adding sterile glycerol to a final 30% v/v concentration to liquid bacterial cultures. 
Glycerol stocks were stored at -80°C. When necessary, from the glycerol stocks an 
overnight culture of bacteria was grown in Luria-Bertani medium [LB medium: per litre: 10 
g Difco Bactotryptone, 5 g Oxoid yeast extract, 10 g NaCl, (pH 7.5)]. Bacterial growth 
media were sterilized before use by autoclaving. When appropriate, ampicillin was added to 
the media at a final concentration of 200 pg /ml.
6.5 Cell culture
The cell line used for transfection and cotransfection experiments were:
a) HeLa cells, an immortal cell line derived from cervical cancer cells.
b) COS-1 cell, an immortal cell line is derived from CV-1 simian cells.
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6.6 DNA preparation
6.6.1 Small scale preparation of plasmid DNA from bacterial cultures
The alkaline lysis of recombinant bacteria was performed by resuspending the bacterial 
pellet in 200 pi of ddH20; 150 pi of solution II (0.2 M NaOH, 1 % w/v SDS) were then 
added and the contents mixed by inversion. 250pl of solution III (3 M potassium acetate pH
5.2) were then added and the contents mixed by inversion. The bacterial lysate was then 
centrifuged in an Eppendorf microcentrifuge at maximum speed and the supernatant 
transferred to a new tube. An equal volume of 1:1 v/v phenolxhloroform solution was 
added to the supernatant. The tube was then vortexed and centrifuged as above. The 
aqueous phase containing the DNA was transferred to a new tube. An equal volume of 
chloroform was added to the supernatant. The tube was then vortexed and centrifuged as 
above. The aqueous phase containing the DNA was then recovered and the DNA pelleted 
by ethanol precipitation. The final pellet was resuspended in 50 pi of ddH20 and 5 pi of 
such preparation were routinely taken for analysis by restriction enzyme digests.
6.6.2 Large scale preparations of plasmid DNA from bacterial cultures
For large-scale preparations of plasmid DNA that was necessary for the transfection 
experiments, JetStar purification kit (Genomed) was used according to the manufacturer’s 
instructions. In order to get a good amount of plasmid, an inoculation in 50 ml of LB 
medium is grown overnight at 37°C.
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6.7 RNA preparation from cultured cells
Cultured cells were washed with PBS and RNA extracted using RNA Trizol, (Invitrogen 
inc) according to the manufactures instructions. Briefly, 750ul of Trizol was added/p6 well 
and allowed to incubate for 5 minutes. The solution was subsequently moved to a 1.5ml 
eppendoff tube and 200ul of chloroform was added. After centrifugation at 10000 rpm the 
supernatant was collected and the RNA precipitated with 0.75 vol. of isopropanol. The 
pellet was resuspended in 100 pi of ddH20 and digested with 1U of DNase RNase-free by 
incubation at 37 °C for 30 minutes, and then the RNA was purified by acid phenol 
extraction. The final pellet was resuspended in 35 pi of ddH20 and frozen at -80 °C. The 
RNA quality was checked by electrophoresis on 1% agarose gels.
6.8 Estimation of nucleic acid concentration
The RNA quantity was detected using the Nanodrop spectrophotometer instrument 
(Thermo Scientific) and equal amounts were used for cDNAs synthesis. The ratio of values 
for optical densities measured at 260 nm and 280 nm is considered as 1.8 for pure sample of 
DNA and 2 for RNA and these are reduced by protein contaminants (Sambrook et al., 
1989). Therefore, these values were used to determinate not only the concentration but also 
the purity of the samples.
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6.9 Enzymatic modification of DNA
6.9.1 Restriction enzymes
Restriction endonucleases were used in the construction and analysis of recombinant 
plasmids. Each restriction enzyme functions optimally in a buffer of specific ionic strength. 
All buffers were supplied by the same company that supplied the enzymes and were used 
according to the manufacturer’s instructions.
For analytical digests 100-500 ng of DNA were digested in a volume of 20 pi containing 5 
U of the appropriate restriction enzyme. The reaction was incubated for 2-3 hours at 37 °C. 
Preparative digestion was made of 5-10 pg DNA using the above conditions and 5 U of 
restriction enzyme for pg of DNA in 200 pi reaction volume.
6.9.2 Large fragment of E. coli Polymerase I and T4 Polynucleotide Kinase
These enzymes were used to treat PCR products for blunt-end ligation during 
construction of recombinant plasmids. The large fragment of DNA Polymerase I (Klenow) 
is a proteolytic product of E. coli DNA Polymerase I. It retains polymerization and 3’->5’ 
exonuclease activity, but has lost 5’->3’ exonuclease activity. This was useful for digesting 
specific residues added by Taq DNA polymerase at the 3’ terminus to create compatible 
ends for ligation. T4 Polynucleotide Kinase catalyses the transfer of phosphate from ATP to 
the 5’ hydroxyl terminus of DNA. It was used for example in the addition of 5’-phosphate 
to PCR products to allow subsequent ligation. Klenow fragment (2.5 U) was added to 23 pi 
of PCR product in 5 mM MgCl2 buffer. The mixture was incubated at room temperature for
10 minutes. EDTA to a final concentration of 0.2 mM, ATP to a final concentration of 1 
mM, 10 U of T4 Polynucleotide Kinase and the proper quantity of Kinase buffer were
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added to the above mixture and incubated at 37 °C for 30 min. The enzymes were 
inactivated by incubation at 80 °C for 20 min.
6.9.3 T4 DNA ligase
T4 DNA ligase catalyses the formation of a phosphodiester bond between adjacent 
3’ hydroxyl and 5’ phosphoryl termini in DNA, requiring ATP as a cofactor in this reaction. 
This enzyme was used to join double stranded DNA fragments with compatible sticky or 
blunt ends, during generation of recombinant plasmid DNAs.
20 ng of linearized vector were ligated with a 5-10 fold molar excess of insert in a total 
volume of 20 pi containing IX ligase buffer and 1U of T4 DNA ligase. Reaction was 
carried out at room temperature for 6-12 hours.
In some reactions synthetic oligonucleotide were included in the reaction. In these cases, 
the amounts added to each reaction to obtain inclusion of oligonucleotides in the resulting 
plasmid were about 100 fold molar excess over the DNA vector.
6.10 Agarose gel electrophoresis of DNA
DNA samples were size fractionated by electrophoresis in agarose gels ranging in 
concentrations from 0.8 % w/v (large fragments) to 2 % w/v (small fragments). The gels 
contained ethidium bromide (0.5 pg /ml) and IX TBE. Horizontal gels were routinely used 
for fast analysis of DNA restriction enzyme digests, estimation of DNA concentration, or 
DNA fragment separation prior to elution from the gel. Samples of 20 pi containing IX 
DNA loading buffer were loaded into submerged wells. The gels were electrophoresed at 
50-80 mA in IX TBE running buffer for a time depending on the fragment length expected 
and gel concentration. DNA was visualized by UV trans illumination and the result 
recorded by digital photography.
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6.11 Elution and purification of DNA fragments from agarose gels
This protocol was used to purify small amounts (less than 1 pg) of DNA for sub­
cloning. The DNA samples were electrophoresed onto an agarose gel as described 
previously. The DNA was visualized with UV light and the required DNA fragment band 
was excised from the gel. This lab was cut into pieces, and the JETquick Spin Column 
Technique (Genomed) was used according to the manufacturer’s instructions. Briefly, 600 
pi of gel solubilisation solution LI (NaC104, Na acetate and TBE) were added for each 100
mg of the gel slice pieces and incubated at 55 °C for 15 min vortexing every 5 min. The 
mixture was loaded into a prepared JETquick column and it was centrifuged at maximum 
speed for 1 min. The flowthrough was discarded. 700 pi of washing and reconstituted 
solution L2 (ethanol, NaCl, EDTA and Tris-HCl) were added into the spin column and after 
5 min, the column was centrifuged in the same conditions twice. The flowthrough was 
again discarded both times. To elute the bound DNA, 30-50 pi of pre-warmed sterile water 
were added onto the centre of the silica matrix of the spin column and the system was 
centrifuged for 2 min. The amount of DNA recovered was approximately calculated by UV 
fluorescence of intercalated ethidium bromide in an agarose gel electrophoresis .
6.12 Preparation of bacterial competent cells
Bacterial competent cells, E. Coli strains, were grown overnight in 3 ml of LB at 
37°C. The following day, 300 ml of fresh LB were added and the cells were grown at room 
temperature for 4-5 h until the O D ^  was 0.3-0.4. The cells were then put in ice and
centrifuged at 4 °C and lOOOg for 15 min. The pellet was resuspended in 30 ml of cold TSS 
solution (10% w/v PEG, 5% v/v DMSO, 35mM Mg C12, pH 6.5 in LB medium). The cells 
were aliquoted, rapidly frozen in liquid nitrogen and stored at -80°C. Competence was 
determined by transformation with 0.1 ng of pUC19 and was deemed satisfactory if this 
procedure resulted in more than 100 colonies.
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6.13 Transformation of bacteria
Transformations of ligation reactions were performed using 1/2 of the reaction 
volume. Transformation of clones was carried out using 20 ng of the plasmid DNA. The 
DNA was incubated with 60 pi of competent cells for 20 min on ice and at 42°C for 1.5 
minutes. At this point 60 pi of LB were added and the bacteria allowed to recover for 10 
min at 37 °C. The cells were then spread onto agar plates containing the appropriate 
antibiotic. The plates were then incubated for 12-15 hours. When DNA inserts were cloned 
into p-galactosidase-based virgin plasmids, 25 pi of IPTG 100 mM and 25 pi of X-Gal (4 % 
w/v in dimethylformamide) were spread onto the surface of the agarose before plating to 
facilitate screening of positive clones (white colonies) through identification of (3- 
galactosidase activity (blue colonies).
6.14 Amplification of selected DNA fragments
The polymerase chain reaction was performed on genomic or plasmid DNA 
following the basic protocols of the Roche Diagnostic Taq DNA Polymerases. The volume 
of the reaction was 50 pi. The reaction buffer was: IX Taq buffer, dNTP mix 200 pM each, 
oligonucleotide primers 1 nM each, Taq DNA Polymerase 2.5 U. As DNA template, 0.1 ng 
of plasmid or 100-500 ng of genomic DNA were used for amplification. When a DNA 
fragment longer than 2000bp was amplified, DMSO 3% was also added to the mixture. The 
amplification conditions are described for each particular PCR. The amplifications were 
performed on a Cetus DNA Thermal Cycler (Perkin Elmer) or on a Gene Amp PCR System 
(Applied Biosystems).
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6.15 Sequence analysis for cloning purpose
Sequence analysis of plasmid DNA was performed using the CEQ 2000 sequencer 
(Beckman Coulter) or sequencing service (BMR Genomics). The plasmid DNA of interest 
(approximately 100 ng) was purified through a MicroSpin S-400 HR Column (Amersham 
Pharmacia Biotech). The DNA was then amplified using fluorescent labeled dideoxy 
nucleotide terminators according to the manufacturer’s instructions. The samples were 
analized by loading them into the automatic sequencer.
6.16 Generation of minigenes
6.16.1 PCR-directed mutagenesis
In this thesis several minigenes were generated by PCR-directed mutagenesis and 
this has been done through PCR amplification of the exon under study with its intronic and 
exonic flanking regions. Two steps PCR technique has been used for generating the hybrid 
mutants using different minigenes as a template. A first set of PCR reactions was performed 
using a combination of primers: forward external primer and reverse internal primer and 
forward internal and reverse external primer. The DNA fragments were gel extracted and 
used as templates for a second PCR reaction using both external primers. The DNA insert 
obtained was then cloned into pUC19 vector (Fermentas) using the enzyme restriction site 
Sma I and through sequencing using oligonucleotides Universal For and Rev the absence of 
any other nucleotide variation in the entire amplified fragments was checked. Finally, the 
obtained DNA inserts was digested with the Kpnl and Xbal enzymes (New England 
Biolabs), gel extracted (EuroClone) and ligated with T4 DNA ligase (New England 
Biolabs) into the pcDNA3 plasmid, using the Kpnl and Xbal restriction sites, which carries 
the CMV promoter suitable for cell culture experiments. Constructs were transfected in 
HeLa cell lines and the minigene splicing products were evaluated by reverse transcriptase 
PCR (RT-PCR) analysis using the primers T7 and SP6 (Fig 6.1).
Universal forward
5 ’ GTAAAACGACGGCC AGT3 ’
Universal reverse
5 ’ GAAAC AGCTATGACC AT35
T7
5’TAATACGACTCACTATAGGG3’
SP6
5 ’ ATTT AGGT GAC ACT AT AG AAT A3 ’
pcDNA 3.1
Poly A site
SP6
Figure 6.1. Schematic representation of pcDNA 3.1 minigene. Gray boxes represents the 
three exons amplified from genomic DNA. The minigene contains a functionall 
polyadenylation site at the 3’ end and at the 5’ end a CMV promoter. Black arrows before 
the exons indicate the position of primers,T7 and SP6, used in RT-PCR reaction when 
analyzing the mRNA produced by the minigene.
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6.16.2 Quick Change Mutagenesis PCR method
Mutagenesis was also at times performed using the QuikChange site-directed 
methodology. Briefly, oligonucleotide primers, each complementary to opposite strands of 
the area of interest and carrying the mutant nucleotides are designed and utilized during 
temperature cycling by PfuTurbo DNA polymerase. Incorporation of the oligonucleotide 
primers generates a mutated plasmid containing staggered nicks. Following temperature 
cycling, the product is treated with Dpn I. The Dpn I endonuclease (target sequence: 5'- 
Gm6ATC-3') is specific for methylated and hemimethylated DNA and is used to digest the 
parental DNA template and to select for mutation-containing synthesized DNA. DNA 
isolated from almost all E. coli strains is dam methylated and therefore susceptible to Dpn I 
digestion. The nicked vector DNA containing the desired mutations is then transformed into 
competent cells. The small amount of starting DNA template required to perform this 
method, the high fidelity of the PfuTurbo DNA polymerase, and the low number of thermal 
cycles all contribute to the high mutation efficiency and decreased potential for generating 
random mutations during the reaction (for the primers that were used see section 4.16.3). 
Briefly, two separate primer extension reactions were set up (one for each forward and 
reverse primer) containing:
5 microliters 10X Pfu Buffer (supplied with enzyme)
1 microliter 10 micromolar primer (0.13 microgram 45-mer)
0.1.- 0.2 microgram plasmid template 
1 microliter 10 mM dNTP mix
H2O to a final volume of 50 microliters 
1 microliter Pfu turbo polymerase (Stratagene)
PCR reaction was done using standard conditions:
1. 94 deg, 30 sec
2. 95 deg, 30 sec
141
3. 55 deg, 1 min
4. 68 deg, 2 min/kb up to 10 KB plasmid
Digestion of amplification product was done by adding into a PCR reaction 10 units of Dpn 
I enzyme, mixed well and incubated at 37 deg for at least one hour. 1 microliter of the 
reaction was used to transform DH5a competent cells. 60 microliters of cells on separate 
plates were plated.
6.16.3 A complete list of the primers used in the section 3 in this thesis
The amplifications for the generation of the fragments to clone in the minigene were 
performed through using the following oligonucleotides.
External primers contained restriction sites: the two forward primers introduce a Kpnl cut 
site, and the reverse primers introduces an Xbal cut site.
The ALPP wild type (wt) minigene was constructed by amplifying the genomic human 
DNA from the exon 3 up to the exon 5 using two oligos ALPP FOR WT and ALPP WT 
REV; while the ALPL wt minigene enclosed the exons 4, 5 and 6 using the following 
primers: ALPP WT FOR and ALPP WT REV (see primer list). These wt minigenes were 
then used as backbone for the mutant hybrid minigenes.
The oligonucleotides used for all the constructs are summarized:
External oligos:
ALPL FOR WT
5 ’ CGGGGT ACCCC AT GGGT GT CTCC AC AGT GACGGCTGCCCG3 ’
ALPL REV WT
5 ’ TGCTCT AGAGC ACT AGT C AAT GTCCCT GAT GTT ATGC ATGAGCTGG3 ’
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ALPP WT FOR
5 ’ GGGGT ACCCC AT GGGGGT GT CT ACGGT G AC3 ’
ALPP WT REV
5 ’ T GCT CT AG AGC ACT AGT C AAT GT COAT GTT GG A3 ’
Internal oligos:
ALPP MUT FOR
5 ’ GT GCCGGC ACCGCC ACGGC CT ACCT GT GCG3 ’
ALPP MUT REV
5 ’ GCGGT GCCGGC ACT GT CT GGC AC AT G3 ’
ALPP MUT2 FOR
5 ’ T GC AAC ACC ACCC AGGGGAACGAGGT CAT CT CCGTGATG3 ’ 
ALPP MUT2 REV
5 ’ GGTGGTGTTGCACCGGGAAAAGCGGGCGGTGCACTCAA3 ’ 
ALPP AG FOR
55 TT G AGT GC ACCGCCCGCTTT AACC AG3 ’
ALPP AG REV
5 ’ GGGCCGGT GC ACT C AAGCC AA3 ’
ALPP 1°ESE G>A FOR
5’CATGTGCCAGACAGTgccGCCACAGCCACGGCC3’
ALPP 1°ESE G>A REV
5 ’ GGCCGT GGCT GT GGCggc ACT GT CT GGC AC ATG3 ’
ALPP 1° ESE A>G FOR
5 ’ GTGCCAGACAGTGGAGGCACAGCCACGGCCTAC3 ’
ALPP 1° ESE A>G REV
5 ’ GT AGGCCGT GGCT GT GCCT CC ACT GT CT GGC AC3 ’
ALPP FORN>S
5 ’ T GC AGCCGCC CGCTTTT CCC AGT GC AAC ACGAC3 ’
ALPP REVN>S
5 ’ GTCGT GTT GC ACT GGGAAAAGCGGGCGGCTGC A3 ’
ALPP FOR Q>R
5’ GCCGCCCGCTTTAACCGGTGCAACACGACACGC3 ’
ALPP REV Q>R
5 ’ GCGT GT CGT GTT GC ACCGGTT AAAGCGGGCGGC3 ’
ALPP FOR R>Q
5 ’ CC AGT GC AAC ACGAC AC AGGGC AACGAGGTC ATC3 ’
ALPP REV R>Q
5 ’ GAT GACCT CGTT GCCCT GT GT CGT GTT GC ACTGG3 ’
ALPL FOR 1ESE
C AGGT CCCT G AC AGT GgaGcC ACaGCC ACCGCCT ACCT 
ALPL REV 1ESE
AGGT AGGCGGT GGCtGT GgCtcC ACT GT C AGGGACCTG 
ALPL FOR 2ESE
C AGCC ACT GAGCGT aaCcaGtgc AAC ACgACaCgcGGc AACGAGGTC ACC 
ALPL REV 2ESE
GGT GACCT CGTT CCCgcGGGT GGT GTT gcaCtgGtt ACGCT C AGTGGCTG 
ALPL FOR 3’SS MUT
5 ’ T GTCCCC AGAC AT AC AAT GT AGAC AAAC AGGT CCCTGAC AGTGCCGGC AC3 ’ 
ALPL REV 3’SS MUT
5 ’ CT GGGGAC AGAGAC ACT CT G AC AGGAGAT GGCC AGGCCTTC3 ’
ALPP FOR3’SS MUT
5 ’ CCCACCTGCAGACGTACAACACCAATGCCCATGTGCCAGAC AGTGCCGGC AC 
3’
ALPP REV 3’SS
5 ’ CT GC AGGT GGGAG AGGAGGGT GCT CTT CT CT GGGGC AGAC AC3 ’
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ALPP 1° ESE G>A/A>G FOR
5 ’ CAT GT GCC AG AC AGT GCCGGC AC AGCC A3 ’
ALPP 1° ESE G>A/A>G REV
5 ’ T GGCT GT GCCGGC ACT GT CT GGC AC AT G3 ’
Table 6.1 Oligonucleotides List. List of the primers used for PCR reactions.
The primers and the templates used to yield each mutated minigene are schematically 
represented in the following table (Table 6.1):
Name of 
the hybrid
Primers Template
MUT1 ALPP MUT FOR 
ALPP MUT REV
ALPP WT
MUT2 ALPP MUT2 FOR 
ALPP MUT2 REV
ALPP WT
MUT3 ALPP MUT2 FOR 
ALPP MUT2 REV
MUT2
MUT4 ALPL FOR 1ESE 
ALPL REV 1ESE
ALPL WT
MUT5 ALPL FOR 2ESE 
ALPL REV 2ESE
ALPL WT
MUT6 ALPL FOR 2ESE 
ALPL REV2ESE
MUT4
MUT7 ALPP AG FOR 
ALPP AG REV
ALPP WT
MUT8 ALPP AG FOR 
ALPP AG REV
MUT1
MUT9 ALPP AG FOR MUT2
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ALPP AG REV
MUT10 ALPP AG FOR 
ALPP AG REV
MUT3
MUT11 ALPP 1°ESE G>A FOR 
ALPP 1°ESE G>A REV
ALPP WT
MUT12 ALPP 1° ESE A>G FOR 
ALPP 1°ESE A>G REV
ALPP WT
MUT13 ALPP 1° ESE G>A/A>G FOR 
ALPP 1° ESE G>A/A>G REV
ALPP WT
MUT14 ALPP FORN>S 
ALPP REVN>S
ALPP WT
MUT15 ALPP FOR Q>R 
ALPP REV Q>R
ALPP WT
MUT 16 ALPP FOR R>Q 
ALPP REV R>Q
ALPP WT
MUT17 ALPP FOR R>Q 
ALPP REV R>Q
MUT13
MUT18 ALPP FOR3’SS 
ALPP REV 3’SS
ALPP WT
MUT19 ALPP FOR3’SS 
ALPP REV 3’SS
MUT1
MUT20 ALPP FOR 3’SS 
ALPP REV 3’SS
MUT2
MUT21 ALPP FOR3’SS 
ALPP REV 3’SS
MUT3
MUT22 ALPP FOR3’SS MUT13
ALPP REV 3’SS
MUT23 ALPP FOR 3’SS 
ALPP REV 3’SS
MUT16
MUT23 ALPP FOR 3’SS 
ALPP REV 3’SS
MUT16
MUT24 ALPP FOR 3’SS 
ALPP REV 3’SS
MUT17
MUT25 ALPL FOR 3’SS MUT 
ALPL REV 3’SS MUT
ALPL WT
Table 6.2. Primers and templates used for the creation of each mutated minigene
6.17 Maintenance and analysis of cells in culture
HeLa and COS-lcell lines was grown in Dulbecco’s Mem with Glutamax I (Gibco) 
(Dulbecco’s modified Eagle’s medium with glutamine, sodium pyruvate, pyridoxine and
4.5 g/1 glucose) supplemented with 10% fetal calf serum (Euro Clone) and Antibiotic 
Antimycotic (Sigma) according to the manufacturer’s instructions. Plates containing a 
confluent monolayer of cells were treated with 0.1% w/v trypsin as follows. Cells washed 
with PBS solution, were incubated at 37°C with 1-2 ml of PBS/EDTA/trypsin solution 
(PBS containing 0.04% w/v EDTA and 0.1% w/v trypsin) for 2 minutes or until cells were 
dislodged. After adding 10 ml of media, cells were pelleted by centrifugation and 
resuspended in 5 ml pre-warmed medium. 1-2 ml of this cell suspension was added to 10 
ml medium in a fresh plate and was gently mixed before incubation
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6.18 Transfection of minigene plasmids
The DNA used for transfections was prepared with JetStar purification kit 
(Genomed) as previously described. Liposome-mediated transfections of 3x10(5) HeLa 
cells were performed using Effectene reagent (Qiagen). 0.5 pg of construct DNA was 
mixed with 4 pi of Enhancer for each transfection and the mixture was incubated at room 
temperature for 5 minutes to allow the condensation of the DNA. Then, 5 pi of Effectene 
were added to the mixture and an incubation of 10 minutes has been performed. After the 
addition of 500 pi of complete culture medium the mixture was added to the cells in 3 ml of 
the same medium and incubated at 37°C. After 6 h the medium was replaced with fresh 
medium and 12 h later, the cells were harvested. RNA isolation followed as described.
6.19 mRNA analysis by Polymerase Chain Reaction
6.19.1 cDNA synthesis
In order to synthesize cDNA, the 3 pg of total RNA extracted from cells were mixed 
with random primers (Pharmacia) in a final volume of 20 pi. After denaturation at 70°C the 
RNA and the primer were incubated for 1 hour at 37 °C in the following solution: IX First 
Strand Buffer (Gibco), 10 mM DTT, 1 mM dNTPs, RNase inhibitor 20 U (Ambion) and 
Moloney murine leukemia virus reverse transcriptase 100 U (Gibco). lp l of the cDNA 
reaction mix was used for the PCR analysis.
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6.19.2 cDNA analysis
PCR analysis of cDNA was carried out for 35 cycles (94 °C 30 sec, 58 °C 30 sec, 72 
°C 1 min) in 50 jil reaction volumes using the following oligonucleotides which recognize 
specific regions of the pcDNA3 expression vector. Finally the PCR products representing 
the splicing products were separated on 2% agarose gels and ethidium bromide-stained. 
Quantification of band intensities in the acquired pictures was performed using the 
ImageJ64 software (available at http://rsb.info.nih.gov/ij).
Oligonucleotide name pcDNA3 vector Sequence of the oligonucleotide (5’-3’)
T7 AAT ACG ACT C ACT AT AG
SP6 ATTTAGGTGACACTATAGAATA
6.20 Construction of the expression plasmids.
The PLAP and TNAP cDNA vectors were provided by JL Millan (Sanford- 
Burnham Medical Research Institute, USA). To facilitate isolation of the recombinant 
enzymes, a FLAG epitope was introduced after the Leu489 and Thr483 in TNAP and 
PLAP, respectively, followed by a termination codon to eliminate the 
glycosylphosphatidylinositol anchoring signal. The PLAP-FLAG mutants were generated 
by Quick change PCR amplification using Pful polymerase followed by Dpnl digestion 
(Promega). Constructs were sequenced to verify the correct introduction of mutations into 
the sequence.
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Name of
the expression
plasmids
Primers Template
PLAP-FLAG 1st 
ESE
[A93G;G94A]
ALPP 1° ESE G>A/A>G FOR 
ALPP 1° ESE G>A/A>G REV
PLAP-FLAG WT
PLAP-FLAG 2nd 
ESE [R125Q]
ALPP FOR R>Q 
ALPP REV R>Q
PLAP-FLAG WT
PLAP-FLAG 
l st/2nd ESE 
[A93G;G94A; 
R125Q]
ALPP FOR R>Q 
ALPP REVR>Q
PLAP-FLAG 1st 
ESE
[A93G;G94A]
6.20.1 Transfection of expression plasmids
The expression constructs were transfected into COS-1 cells for transient expression 
by the Effectene transfection reagent (Quiagen). Cells were transfected with 5 pg of FLAG- 
tagged expression consctructs. Transfected cells were cultured in OPTI-MEM serum free 
medium, and conditioned media (25ml/150 mm plate), containing secreted wt and mutant 
enzymes, were collected 48 hours after transfection.
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6.21 Purification of FLAG-tagged enzymes
Each secreted FLAG-tagged mutant enzyme was purified using an anti-FLAG M2 
monoclonal antibody affinity column (Sigma, St. Louis, MO, USA).
The anti-flag M2 monoclonal antibodies agarose was first packed into chromatographic 
column. The anti-flag column was equilibrated with TBS for at least 10 bed-volumes. The 
conditioned media (25ml/150 mm plate), containing secreted enzyme was then loaded onto 
the column at the flow rate of 1 ml/min. Contaminating proteins were washed out with 10- 
20 column volumes TBS buffer. Then, the protein fused with the C-terminal Flag tag was 
eluted with 1ml of elution buffer (100 mM Glycine, pH 3.5). Each 1 ml of eluted fractions 
was collected in a 1.5 ml tube containing 20 pi Tris-HCl (1 M, pH 8.8) for neutralization. 
The column was then extensively washed with 10-20 column volumes TBS buffer and 
stored in storing buffer (TBS buffer, 50% glycerol, pH 7.5) at 4°C for the long-term 
storage.
6.22 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins from each sample were mixed with 10X protein loading buffer (20% w/v 
SDS, 1M DTT, 0.63M Tris-HCl pH 7, 0.2% w/v bromophenol blue, 20% v/v glycerol, 
lOmM EDTA pH 7). Conventional slab gel SDS PAGE (Laemmli, 1970) was performed in 
vertical gels with the required percentage of polyacrylamide (37,5:1 acrylamideibis- 
acrylamide, ProtoGel, National Diagnostics), depending on each case. The gels were run at 
40 mA in IX SDS-PAGE running buffer (50 mM Tris, 0.38 M glycine, 0.1 % w/v SDS). 
After running, gels were either stained with coomassie Blue R250 in methanol-water-acetic 
acid 45:45:10 (v/v/v) or Western blot analysis was performed.
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6.23 Western blots and antibodies
SDS-PAGE gels were blotted on standard nitrocellulose membrane and incubated in 
blocking solution (PBSIX, 0.2% Tween, 2% milk) over night. Primary antibodies were 
incubated with the membrane in the same buffer for 2 hours. Afterwards, the membrane 
was then washed three times in washing solution (PBS IX, 2%Tween), incubated with the 
proper HRP-secondary antibodies (anti-mouse/rabbit, Dako) for 1 hour, washed twice and 
stained with ECL reagent (Thermo Scientific). Finally, an autoradiography was taken on 
Kodak Biomax XAR films.
The primary antibody used in this study: Anti-flag epitope: (1:2000) (Sigma FI 804)
6.24 Micro Bicinchoninic Acid (BCA) Protein Assay
Micro Bicinchoninic Acid (BCA) Protein Assay (Pierce) for determining the protein 
concentration of dilute samples (0.5 - 20pg/mL).
The Micro BCA Protein Assay is a highly sensitive colorimetric assay primarily relies on 
two reactions. Firstly, the peptide bonds in the protein sample reduce Cu2+ ions, in a 
temperature dependent reaction, from the copper solution to Cu+. The amount of Cu2+ 
reduced is proportional to the amount of protein present in the solution. Next, two 
molecules of BCA chelate with each Cu+ ion form a purple-colored product that strongly 
absorbs light at a wavelength of 562 nm. The amount of protein present in a solution can be 
quantified by measuring the absorption spectra and the standard curve is obtained by 
plotting the absorbance (Abs) versus known concentration of standard protein.
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6.25 Immune Enzymatic Assay PLAP/TNAP
The principle of the assay was based on the measurement of relative specific enzymatic 
activities using microtiter plates coated with 0,2 pg/ml M2 anti-Flag antibody in TBS, 
MgCl2 ImM and ZnAc 20 pM. Each well was blocked with 200 pi 1% BSA. The plate was 
washed five times with washing buffer (working buffer + 0,002 % Tween 20). Saturating 
concentration of sample was added to each well for 3 hours at RT. After washing, 
increasing concentration of />-nitropheny lphosphate (pNPP, Sigma) (0.01 - 20 mM final 
concn.) in 1.0 M diethanolamine (DEA) buffer, pH 9.8, containing 20 pM ZnC12 and 1 mM 
MgC12 was added as substrate and the activity was measured directly the at 405 nm during 
the time. For the calculation of catalytic rate constants, the wt PLAP-FLAG construct with 
a known kcat is used as a reference for each microtiter plate.
6.26 Slot blot protein determination
The enzyme concentration of each purified sample was determined by the Bio-Dot SF 
Apparatus (Bio-Rad) using Amino-terminal FLAG-Bacterial Alkaline Phosphatase (BAP) 
Fusion protein (Sigma) as a standard (Zhu et al., 2005). 96-well plates (Nunc MaxiSorp®) 
were blocked with 400 pl/well blocking buffer (3% skim milk in PBS) at room temperature 
for 30 min. The plates were washed five times with PBS/ 0.01% Tween 20 (PBST, Sigma). 
Eight two-fold serial dilutions of FLAG-BAP standard protein and purified enzymes were 
prepared with PBS in the blocked plates. The FLAG-BAP standard dilutions ranged from
3.5 to 225 ng. The proteins were applied to the slot blot apparatus and drown by vacuum 
through a pre-wetted nitrocellulose membrane (0.45 pM, Amersham Biosciences). The 
membrane slot was washed by drawing two times 300 pi of PBS through each well, and 
was incubated for 1 hour at room temperature with blocking solution (5% skim milk in 
PBS). The membrane was than incubated 2h at room temperature or, alternatively overnight
at 4°C 1:1000 dilution of M2 anti-FLAG antibody (Sigma). The membrane was washed 
three times with PBST, and was incubated for 1 hour at room temperature with 1:2000 
dilution with the secondary anti-mouse antibody conjugated with horseradish peroxidase for 
1 hour (Dako Cytomation). The membrane was then washed again three times with PBST 
and developed using the Pierce Chemi-Luminescen (ECL) western blotting substrate. The 
membrane was scanned and the intensity of each band on the slot was measured with 
ImageJ64 Software. Thus each peak in the graph represented a slot containing detected 
protein. Standard curves were obtained (using excel) by plotting peak area versus known 
concentration of FLAG-BAP and fitting the data points with linear regression equation. The 
peak areas of the serially diluted purified protein samples that fell within the detection 
range of each respective standard curve were used to calculate the protein concentration. 
Generally the mean value of 4 peaks from each protein dilution series is used per assay. The 
standard curve was included in every slot.
6.27 ALP assay and Kinetic measurements
ALP kinetic determinations were performed as described previously (Hoylaerts et 
al., 1992) in presence of increasing concentration of j9-nitrophenylphosphate (pNPP, Sigma) 
(0.01 - 20 mM final concn.) as substrate in 1.0 M diethanolamine (DEA) buffer, pH 9.8, 
containing 20 pM ZnC12 and 1 mM MgC12. After the addition of recombinant ALPs (8 ng), 
the activity was measured as the change in absorbance at 405 nm over time at 37 °C. The 
kinetic analysis was done from those parts of the curve where the absorbance versus time 
was linear (15 min). To determine the initial rate, the AAbs^s/min was calculated taking 
into the account an extinction coefficient for reaction product p-nitrophenol of 12.2 xlO3 M' 
1 cm'1. The AAbs^/min corresponds to an increase in the concentration of the product, p- 
nitrophenol, per minute (Ac/ minute) and an equal decrease in the concentration of the 
substrate. The corresponding Ac/minute can be determined by using the extinction
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coefficient absorption coefficient (s) for /?-nitrophenol using Beer’s law (A = 8 x 1 x c, 
where 1 = path length (usually 1 cm), c = concentration of p-nitrophenol, and e = extinction 
coefficient, in this case 12.2 xlO3 M’1 cm’1). This Ac/min is also known as v0, the initial 
velocity. Eleven different substrate concentration were used to measure the Km and Vmax 
and the resulting v0 were fit by nonlinear regression to the Michaelis-Menten equation using 
GraphPad Prism version 3.02 (GraphPad Software, San Diego, CA). The Kcat was 
calculated dividing the Vmax for the concentration of enzyme used for each reaction.
6.28 Statistical analysis
The Km and Vmax values were calculated from 6 independent experiments. The 
statistical software R version 2.13.1 was used for statistical analysis. All values were 
checked for normal distribution by the Shapiro-Wilk normality test. Data from WT and 
mutants enzymes showed normal distribution and were expressed as mean values (± SD). 
Differences between mean values were analyzed using the Student's t-test.
The asterisks indicate the range of the different P values as shown in the scheme below:
P-value Symbol
P<0.05 *
P<0.01 **
PC0.001 ***
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